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Aliphatic polycarbonates are fast emerging as a highly valuable class of 
biomaterials due to their inherent biocompatibility, biodegradability, facile synthesis, 
and ease of tailoring functionalities to meet specific requirements of various 
applications. In the field of gene delivery, polycarbonates are less widely documented 
and there lies great potential and scope for novel research. The overall goal of this 
thesis is thus to design and evaluate a versatile class of biodegradable cationic 
polycarbonates and their copolymers for gene delivery. We hypothesized that the 
cationic polycarbonates with well-controlled molecular weights and narrow 
polydispersities imparted by metal-free living organocatalytic ring-opening 
polymerization of functionalized cyclic carbonate monomers, followed by a 
subsequent quaternization reaction with bis-tertiary amines, are safe and effective 
gene carriers. 
 
To test our hypothesis, we explored three specific aims: 
(1) Rationally design and evaluate the gene transfection ability and cytotoxicity of 
novel cationic polycarbonates bearing quaternary and tertiary amines in the 
side chains. 
(2) Enhance the stability of DNA complexes through the design of block 
copolymers of poly(ethylene glycol) (PEG) and cationic polycarbonates; and 
investigate the effects of PEG configuration within block copolymers on key 
aspects of gene delivery. 
(3) Examine the efficacy of galactose-functionalized polycarbonate block 





In Aim (1), we described the rational design of cationic polycarbonates with key 
features such as a biodegradable backbone as well as quaternary and tertiary amines 
in the side chains for DNA binding and endosomal buffering, respectively. It was 
demonstrated that the cationic polycarbonate efficiently condensed DNA into 
positively charged nanoparticles that induced high luciferase gene expression that was 
comparable or superior to the commercially available branched 25 kDa 
polyethylenimine benchmark in a panel of mammalian cell lines with minimal 
cytotoxicities. In Aim (2), diblock PEG-b-cationic polycarbonate and triblock cationic 
polycarbonate-b-PEG-b-cationic polycarbonate block copolymers were designed to 
capitalize on the highly desirable in vivo properties of the PEG macroinitiator. We 
demonstrated for the first time that PEG configuration within block copolymers has 
an influence on the key aspects of gene delivery. DNA complexes formed with the 
triblock copolymer in particular, exhibited more favourable physicochemical (size, 
zeta-potential and colloidal stability) and biological properties (cellular uptake and 
gene transfection in HepG2) than that formed with the diblock copolymer and non-
PEGylated control. In Aim (3), galactose-functionalized cationic polycarbonate block 
copolymer (Gal-APC) was designed to mediate active targeting of DNA to the 
asialoglycoprotein-receptor (ASGP-R) expressing hepatocytes. It was shown that the 
Gal-APC/DNA complexes induced significantly higher luciferase expression in the 
ASGP-R positive HepG2 than the corresponding glucose-functionalized control. Co-
incubation with a natural ligand for the ASGP-R, asialofetuin resulted in a decrease in 





In conclusion, the findings of this thesis supported the hypothesis that amine-
functionalized cationic polycarbonates and their copolymers are safe and efficacious 
non-viral vectors for gene delivery. Gal-APC is presented as a promising candidate 
for further preclinical evaluations to be used for the gene therapy of hepatocellular 
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CHAPTER 1. Introduction 
 
1.1. Gene therapy: Major developments and current status 
Gene therapy is defined as the treatment of human disease by the delivery of 
genetic material into specific cells of the patient to replace or correct defective genes 
[1]. The tremendous advancements in molecular biology coupled with the completion 
of the Human Genome Project in 2003 have provided valuable information on the 
identity of numerous disease-causing genes. The delivery of genes to replace or 
augment naturally occurring proteins is thus believed to hold immense potential for 
the treatment of countless incurable or difficult-to-treat genetic and acquired diseases. 
In the past two decades, gene therapy has been heavily investigated worldwide with 
more than 1714 clinical trials that have been completed or are ongoing as of June 
2011 [2]. Gene delivery vectors can be broadly classified into 2 classes, namely viral 
and non-viral (Figure 1.1). Viral vectors are the earliest and most common gene 
carriers investigated to date, accounting for more than 68% of the total clinical trials. 
The first successful gene therapy was reported in April 2000 for the treatment of 
severe combined immunodeficiency (SCID) in infants using retroviral vectors [3]. 
Shortly after, several other clinical trials using viral vectors similarly posted 
promising results [4, 5]. The elation, however, was short-lived when the patients 
subsequently developed leukemia-like disorders attributed to the retroviral insertion 
near the promoter of a proto-oncogene [6]. This incident, together with the death of 
the 18-year old Jesse Gelsinger from fatal inflammatory responses to the adenoviral 
vector used in the ornithine transcarbamylase deficiency trial in 1999 [7] have casted 
a shadow over the safety of viral vectors. Non-viral vectors were developed as safer 




have limited their use in clinical trials (Figure 1.1). Behind the use of naked DNA, 
lipid-based carriers are the next most commonly used class of non-viral vectors 
(6.4%). Despite the large number of gene therapy clinical trials performed to date, the 
incidence of success remains disappointingly low. Therefore, continued efforts to 
develop safe and efficient gene vectors are urgently required before the immense 
potential of gene therapy in medicine can be fully realized. The past failures observed 
with the use of viral vectors have also greatly highlighted the need to have a better 
understanding of the gene carriers prior to their use in clinical applications. In this 
Chapter, we will first provide an overview on the common classes of viral and non-
viral vectors investigated for gene delivery. The merits and limitations of each type of 
vector will be examined in each subsection. Subsequently, the barriers restricting the 
success of in vivo gene delivery and the strategies that have been employed to 
overcome them (with focus on the more versatile cationic polymeric gene carriers) 
will be discussed. Lastly, we will provide perspectives for the future development of 
gene therapy. 
                   
Adenovirus 24.2% (n=414) Retrovirus 20.7% (n=355)
Naked/Plasmid DNA 18.7% (n=320) Vaccinia virus 8.1% (n=138)
Lipofection 6.4% (n=109) Poxvirus 5.5% (n=94)
Adeno-associated virus 4.7% (n=81) Herpes simplex virus 3.3% (n=57)





Figure 1.1. Types of vectors used in gene therapy clinical trials. Chart reproduced 
with permission from the Journal of Gene Medicine Clinical Trial Database [2]. 
Copyright (2011) John Wiley and Sons Ltd. 
 
1.2. Methods of gene delivery 
 Existing approaches for gene delivery include mechanical, electrical, viral and 
non-viral methods. Mechanical (including microinjection, hydrodynamic injection 
and particle bombardment) and electrical methods (i.e. electroporation) of gene 
delivery have previously been reviewed by Luo and Saltzman [8]. Although these 
methods are fairly effective, they are technically challenging to harness for most in 
vivo applications and significant concerns over the selectivity, toxicity and long-term 
safety of these methods persist. Further, naked DNA is highly susceptible to both 
extra- and intra-cellular degradation by nucleases. Packaging strategies using viral 
and non-viral vectors are undeniably more effective at protecting DNA and 
facilitating cell membrane penetration. Therefore, in this section, we will focus on the 
viral and non-viral class of gene vectors that either have already been utilized in 
clinical trials or have demonstrated potential to be used for a wide range of systemic 
gene delivery applications. The advantages and disadvantages for each type of vector 
will also be evaluated.  
 
1.2.1. Viral 
Recombinant viral vectors are the most efficient class of gene carriers reported to 
date. These gene delivery vectors comprise of a vector DNA in which most of the 
coding regions from the viral genome is replaced with a therapeutic gene cassette, 
leaving only the non-coding cis-acting elements required for functions such as the 




into the host chromatin (Figure 1.2) [6, 9, 10]. Viral genes encoding for structural and 
replication proteins are segregated and introduced as helper DNA which are delivered 
as heterologous plasmids or incorporated into the chromosomal DNA of the 
packaging cell. The presence of a packaging domain in the vector DNA, but not the 
helper DNA, ensures that only the vector DNA can be packaged into viral particles, 
essentially producing replication-defective viral particles that retain the ability to 
exploit the viral infection pathway for cellular delivery of genetic cargoes. 
Additionally, the split construct design incorporated in a packaging cell line is 
believed to enhance the biosafety of the vector by making it more difficult to 
reconstruct a replication-competent genome as a greater number of recombination 
events is now needed [9].   
                   
Figure 1.2. Engineering of a virus into a gene vector. The helper DNA contains viral 
genes encoding for structural proteins and proteins essential for vector DNA 
replication. It can be delivered as a plasmid or helper virus, or be stably integrated 
into the chromosomal DNA of the packaging cell. As the gene sequences responsible 
for pathogenicity and encapsidation (ψ -) have been eliminated, the helper construct 
cannot be packaged into a viral particle. The vector DNA contains the therapeutic 
gene cassette and the non-coding cis-acting elements with a packaging domain (ψ). 
Viral replication and structural proteins are expressed from the helper DNA, leading 




particles upon recognition of the packaging domain by the structural proteins. 
Reproduced with permission from [9]. Copyright (2010) Nature Publishing Group. 
 
The five main classes of clinically applicable viral vectors are derived from 
retroviruses, lentiviruses, adenoviruses, adeno-associated viruses (AAVs) and herpes 
simplex viruses (HSVs) [6, 9, 10]. These vectors can be divided into 2 categories, 
depending on whether their genomes integrate into host chromatin (including 
retroviral- and lentiviral-vectors) or if they persist in the cell nucleus as episomes, 
which are stable DNA molecules that do not integrate into the host’s genome 
(including adenoviral-, AAV- and herpes viral-vectors). 
Retroviruses are lipid-enveloped particles containing single-stranded RNA with a 
size ranging from 7 to 11 kb. Upon entry into cells, the RNA is reverse-transcribed 
into linear double-stranded DNA which is then integrated into the host’s chromatin. 
The accessibility of the cis-acting elements in the viral genome has facilitated the 
engineering of the retroviral vectors, making them the earliest and most commonly 
used vector in gene therapy clinical trials to date. A key limitation of the retroviral 
vectors lies in their inability to cross the intact nuclear membrane to transduce non-
dividing cells. This effectively limits the use of retroviral vectors mainly for gene 
delivery to dividing tumor cells and ex vivo transduction of lymphocytes and 
hematopoietic progenitor cells. Although the retroviral vector integrates efficiently 
into the host chromatin and could potentially mediate persistent gene expression in 
dividing cells, stable expression of the transgene is not guaranteed as it can be 
gradually silenced over time. 
 Lentiviruses including the human immunodeficiency virus type 1, the simian 
immunodeficiency virus and feline immunodeficiency virus are part of the retrovirus 




to penetrate the intact nuclear membrane to efficiently transduce and integrate the 
vector genome into the host chromatin of non-proliferating cells. This characteristic 
has conferred broad tropism to the lentiviral vectors and has allowed for the ex vivo 
transduction of hematopoietic stem cells without the need for prior cytokine-induced 
cell proliferation. Common to the other retroviruses, non-specific integration into the 
host genome could potentially activate transcription of oncogenes. The duration of 
gene expression should also be further evaluated.  
Adenoviruses are non-enveloped viruses containing a double-stranded linear DNA 
genome. The advantages of adenoviral vectors include high transduction efficiency, 
broad tropism and relative ease of large scale production. Poor sustained transgene 
expression and induction of potent immune responses are the main problems 
associated with this class of vectors [7].  
AAVs are human parvoviruses that are dependent on extra genes from 
adenoviruses or herpes viruses for replication. AAV-derived vectors transduce cells 
mainly through episomal transgene expression (> 90%) and random integration into 
host chromatin (< 10%) [6]. The advantages of AAVs include broad tropism, 
sustained gene expression, low toxicity and minimal inflammatory responses. 
Disadvantages include difficulties in scaling up production and a restriction in the size 
of the gene that can be delivered (typically < 4.5 kb) [10]. 
HSVs are enveloped viruses bearing linear double-stranded DNA genome of 152 
kb. HSV type 1 (HSV-1) is the most commonly engineered herpes virus due to the 
vector’s capacity for large transgene size of up to 40 kb [6]. An attractive feature of 
this viral vector is its high transduction efficiency in a large number of cell types. 
Limitations include difficulties in achieving long-term transgene expression and lack 




Viral vector hybrids that combine the properties of different viruses, for instance 
cellular internalization and nuclear targeting of adenovirus and site-specific 
integration of AAV, have also been investigated for gene delivery.  
 
1.2.2. Non-viral 
Although viral vectors are extremely efficient at delivering therapeutic DNA into 
cells, their use has been associated with serious safety concerns such as potent 
inflammatory responses and carcinogenic risks [6, 9, 10]. Other limitations as 
discussed in Section 1.2.1 include high cost and technical difficulties involved in 
scaling up production, lack of cell specificity, size restrictions on the gene 
encapsulated, and risk of vector reversion into replication-competent viruses. Non-
viral vectors have been proposed to be highly promising alternatives for overcoming 
the safety issues of viral vectors as they are expected to possess significantly lower 
immunogenic and carcinogenic risks [11, 12]. Synthetic non-viral vectors, in 
particular, are generally more amendable to large-scale and cost-effective preparation 
and have no restrictions on the size of therapeutic gene being delivered. However, the 
major drawback to their widespread application lies in their relatively low efficiencies 
compared to their viral counterparts brought about by the seemingly colossal extra- 
and intra-cellular barriers that have to be surmounted (to be discussed in Section 1.3). 
Fortunately, advancements in synthetic methodologies have afforded great 
flexibilities for the modular design of non-viral vectors to overcome physiological 
barriers for safe and efficient gene delivery compared to the viral vectors. In this 
Section, we will introduce the major classes of non-viral vectors including the 





1.2.2.1. Cationic liposomes 
Cationic liposomes are the most extensively investigated non-viral vectors for gene 
delivery and are typically comprised of a cationic lipid with a neutral helper lipid [13-
16]. Structurally, cationic lipids are composed of a positively charged head group 
bridged by a linker to a hydrophobic lipid domain. Common hydrophilic head groups 
employed for gene delivery includes monoamines such as tertiary or quaternary 
amines, polyamines, amino acids [17], amidinium, pyridinium or guadinium salts. 
The main function of the cationic head group is to electrostatically bind and condense 
negatively charged DNA to form positively charged nanoparticles for enhanced 
cellular uptake and in the examples of multivalent head groups such as 2,3-
dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-l-propanaminium 
trifluoroacetate (DOSPA) and di-octadecyl-amido-glycyl-spermine (DOGS), function 
to mediate endosomal escape of the lipoplexes [16, 18]. The hydrophobic domain is 
usually made up of aliphatic fatty acid chains or steroids such as cholesterol. The type, 
alkyl chain length, degree of unsaturation, and configuration of the hydrophobic 
chain(s) have been found to influence gene transfection to varying degrees. In general, 
cationic lipids bearing two linear fatty acid chains offers more efficient gene 
transfection and are less toxic. Also, higher gene transfection has been observed with 
an increased degree of unsaturation in the alkyl chains of cationic lipids presumably 
due to an enhancement in membrane fluidity and fusogenicity. In a study by Zhu et al., 
it was also demonstrated that trans-oriented pyridinium mono-unsaturated cationic 
lipids displayed enhanced gene transfection over their cis-oriented counterparts 
regardless of the hydrophobic chain length [19]. The effect of alkyl chain length on 
gene transfection is less straightforward and is found to differ with the accompanying 




amide, and carbamate. The chemical stability and biodegradability of the chosen 
linker group are known to have a profound impact on the overall toxicity, stability and 
transfection efficiency of the lipoplexes. Although all three cationic lipid components 
have been investigated extensively, it is the combination of the properties conferred 
by all the components within the lipid molecule that greatly influence gene delivery.   
Cationic liposomes formulated with neutral helper lipids, in particular 
dioleoylphosphatidylethanolamine (DOPE) and cholesterol, are more effective at 
mediating gene transfection and are less toxic compared to the single cationic lipid 
formulation or the use of other helper lipids such as dioleoylphosphatidylcholine 
(DOPC) [15]. This effect is attributed to the ability of DOPE to undergo phase 
transition from a bilayer structure with the cationic lipid to an inverted hexagonal 
structure under acidic pH, which is believed to facilitate the fusion and destabilization 
of cellular and endosomal membranes. The inclusion of cholesterol in cationic 
liposomes enhances the liposomal physical and chemical stability and has been 
reported to confer superior gene transfection in vivo [15, 20]. In addition to the nature 
of the cationic and helper lipids, numerous other factors such as stoichiometric ratio 
of cationic lipid and DNA and method of preparation of lipoplexes also influence the 
gene transfection efficiency and toxicity of the lipoplexes and have been extensively 
reviewed elsewhere [15].  
 
1.2.2.2. Cationic polymers  
Similar to cationic liposomes, cationic polymers offer protection against nuclease 
degradation by compacting DNA into slightly positively charged nanoparticles which 
display prolonged blood circulation time, enhanced tissue accumulation and improved 




we will discuss the common classes of cationic polymer-based gene delivery vectors, 
including poly-L-lysine, poly(ethylenimine) and dendrimers as well as introduce the 
biodegradable class of cationic polymers that have gained prominence for use in gene 
delivery due to their lower cytotoxicities and higher transfection efficiencies 
compared to the conventional classes of polymer-based carriers. 
 
1.2.2.2.1. Poly-L-lysine 
Poly-L-lysine (PLL) is among one of the earliest cationic polymers to be 
investigated for gene delivery [21]. Although PLLs possess good DNA condensation 
properties, their applications in gene delivery are limited by low transfection 
efficiencies, high cytotoxicities and poor stability when used alone without 
modifications [12, 21-23]. The inherently low transfection efficiencies of PLLs is 
primarily due to protonation of all the primary ε-amine groups in the lysine residues at 
physiological pH, thus making them unavailable to function as a proton sponge in the 
acidic endosomal environment. Co-incubation of cells with PLL/DNA complexes and 
the weak base chloroquine or fusogenic peptides has been found to improve gene 
transfection, however, the innate cellular toxicity of the endosomolytic agents restricts 
their use in vivo. Chemical conjugation of the ε-amine groups of PLL with endosomal 
escape moieties such as histidine [24, 25] and imidazole groups [26] has been 
reported to improve gene transfection. The conjugation of PLL with targeting ligands 
has also been employed to enhance gene transfection efficiencies and reduce toxicities. 
The first targeting approach for PLL was reported in the late 1980s by Wu and Wu 
who demonstrated that the conjugation of PLL with the ligand asialoorosomucoid 
selectively enhanced gene expression in asialoglycoprotein receptor-expressing 




stability of PLL/DNA complexes, researchers have also conjugated hydrophilic 
moieties, most commonly poly(ethylene glycol) (PEG), to PLL. For instance, 
Kataoka’s group reported polyion complex (PIC) micelles self-assembled from 
electrostatic interactions between PEG-PLL block copolymers with DNA and 
demonstrated the ability of the PEG palisade to offer protection against nuclease 
degradation of DNA and to confer serum stability [29, 30]. In the subsequent in vivo 
study, the PIC micelles displayed prolonged blood circulation compared to naked 
DNA and induced gene expression in the liver for up to three days [31]. Although the 
early studies with PLL were promising, the poor biodegradability and relatively low 
transfection efficiency particularly in the absence of endosomal buffering moieties 
have restricted their applications [12]. 
  
1.2.2.2.2. Poly(ethylenimine) 
Poly(ethylenimine) (PEI) was first introduced by Boussif et al. in 1995 as a 
versatile vector for the highly efficient delivery of plasmid DNA and oligonucleotides 
[32]. Since the first report, PEI have been widely regarded as the ‘gold standard’ of 
non-viral gene vectors due to its superior gene transfection capabilities in a variety of 
transformed cell lines, primary cells, and animal models [32-34]. To date, extensive 
modifications have been made to branched and linear structures of PEI for various 
gene delivery applications (reviewed in [35, 36]). The high gene transfection 
efficiency of PEI is widely attributed to its high cationic charge density and its 
extremely efficient role as a ‘proton sponge’ [12]. Linear PEI is comprised of 
secondary amines in its backbone (except for the terminal groups), while 
commercially available branched PEI contains primary, secondary and tertiary amines 




present in PEI, a large percentage of amines remain unprotonated at both 
physiological and endosomal pH, and could therefore aid in endosomal buffering [38]. 
Briefly, after endocytosis, the protonation of amines in PEI results in the ATPase-
mediated active transport of protons and the accompanying chloride ions in a process 
to maintain the acidic pH of the endosome. This leads to increased osmotic pressure, 
which consequently results in endosomal swelling, rupture, and the release of the 
PEI/DNA complexes into the cytosol, hence circumventing the lysosomal degradation 
pathway. Among various PEI molecular weights and structures, branched 25 kDa and 
linear 22 or 25 kDa PEIs have emerged as more suitable candidates for gene 
transfection as they generally exhibit more favorable physicochemical properties, 
stability, cytotoxicity profile as well as in vitro and/or in vivo gene transfection [33, 
34, 39-41]. As such, they are routinely used as the benchmark for the investigation 
and evaluation of new non-viral vectors for gene delivery applications. 
Although the gene transfection efficiencies of both branched and linear PEI remain 
superior to many of the non-viral gene vectors currently available, the major obstacle 
to their widespread clinical use is the pronounced in vitro and in vivo toxicity [16]. In 
general, higher molecular weight PEIs have been found to induce greater cytotoxicity 
than their low molecular weight counterparts presumably due to their higher charge 
densities [41-43]. In a study by Fischer et al., it was demonstrated that large 
molecular weight PEI, but not low molecular weight PEI, aggregated to form large 
clusters on the outer surface of the plasma membrane, leading to necrosis [42]. A 
higher degree of branching has also been found to increase the cytotoxicity and 
hemolytic properties of PEI-based polymers [44]. Another drawback associated with 
the use of PEI/DNA complexes lies in their propensity for non-specific interactions 




reticuloendothelial system. For instance, Ogris et al. reported that DNA complexes 
formed with transferrin-PEI (800 kDa) aggregated in plasma, induced aggregation of 
red blood cells and bound to various plasma proteins such as immunoglobulin M, 
fibrinogen, fibronectin and complement C3 [45]. The non-biodegradability of PEI is 
also a major drawback for in vivo applications due to the limited renal clearance, 




Dendrimers are well-defined three dimensional macromolecules comprising of a 
central core from which a number of highly branched arms emanate in an ordered and 
symmetric manner to form tree-like structures [16, 23, 46]. Dendrimers are usually 
prepared by step-wise synthesis via either the convergent or divergent method. In the 
first method, the branch arms are grown outwards from a multifunctional core, 
whereas in the second method, the branch chains are grown inwards from peripheral 
end-groups and eventually terminate at the central core. The full completion of each 
reaction step adds a distinct layer to yield one dendrimer generation. The well-
controlled synthesis endows dendrimers with unique architectural features such as a 
well-defined spherical or planar-elliptical core-shell structure with low 
polydispersities. The lower chain densities in the inner core structure confers space 
for loading of small drug molecules while the terminal functional groups present on 
the shell surface provide excellent opportunities for DNA binding and surface 
modifications. At present, the commercially available cationic dendrimers 
poly(amidoamine) (PAMAM) (Starburst®) and poly(propylenimine) (PPI) 




dendrimers are typically synthesized via a divergent method using ethylenimine or 
ammonia as a core for esterification with methylacrylate, followed by amidation of 
the resultant ester groups with ethylenimine [47]. PPI is also divergently synthesized 
using a butylenediamine core for the Michael addition of acrylonitryl, followed by a 
final hydrogenation of the nitrile groups [48]. Several characteristics within PAMAM 
and PPI dendrimers are favorable for gene delivery and they include: 1) primary and 
tertiary amines to undergo electrostatic interactions with DNA to form nanoparticles 
(dendriplexes) and 2) an abundance of tertiary amines in the core to offer buffering 
capacities that facilitates endosomal escape of the dendriplexes following endocytic 
uptake. Generally, an increase in generation number (or charge density) leads to an 
increase in cellular uptake [49] and gene transfection [50], however, an increase in 
cytotoxicity and hemolytic activities often results [46, 51, 52].  
         
Figure 1.3. Structures of commonly used cationic dendrimers, poly(amidoamine) 
(PAMAM) and poly(propylenimine) (PPI), in gene delivery. Reproduced with 
permission from [53]. Copyright (2005) Nature Publishing Group. 
 
The presence of multiple functional groups within dendrimers has been identified 




biocompatibility, cellular targeting, stability, and etc, for the use of the dendrimers in 
in vivo gene delivery applications. For instance, in efforts to lower the cytotoxicity 
while maintaining a high charge density for DNA binding, Lee et al. replaced the 
surface primary amines of PAMAM dendrimers with hydroxyl groups and 
subsequently performed methylation of the tertiary amines present in the interior of 
the dendrimer to obtain quaternized PAMAM-OH that possessed superior DNA 
binding ability compared to PAMAM-OH and yet was less cytotoxic compared to the 
parent PAMAM structure [54]. More recently, Han et al. reported HAIYPRH (T7)-
conjugated polyethylene glycol-modified PAMAM G5 dendrimer (PAMAM-PEG-T7) 
for co-delivery of doxorubicin (DOX) and a therapeutic gene encoding for human 
tumor necrosis factor-related apoptosis-inducing ligand (pORF-hTRAIL) [55]. In this 
study, the surface primary amines of PAMAM were sequentially conjugated with 
PEG and then functionalized with a T7 peptide, which is a ligand for transferrin 
receptors overexpressed on tumor cells. The targeting functionality in PAMAM-PEG-
T7/pORF-hTRAIL-DOX effectively resulted in higher cellular uptake and luciferase 
gene expression in in vitro studies. Importantly, the co-delivery of DOX and pORF-
hTRAIL using PAMAM-PEG-T7 was found to significantly inhibit tumor growth in 
nude mice bearing Bel-7402 subcutaneous xenografts to a larger extent than the 
controls. In another study, arginine-conjugated PPI G2 dendrimers synthesized by the 
conjugation of arginine residues onto the peripheral primary amine residues of the PPI 
G2 dendrimer were found to be 8-214 times more effective at gene transfection 
compared to unmodified PPI in HeLa and HEK293 cell lines without an obvious 
increase in cytotoxicity despite the higher charge densities [56].  
While most dendritic polymers used are symmetrical structures, numerous other 




hyperbranched polymers are as effective for gene delivery (reviewed in [57]). In fact, 
it has been demononstrated that partially degraded PAMAM dendrimers possess a 
more flexible structure for DNA interaction to form more compact complexes which 
are more favorable for endocytic uptake [58].  
 
1.2.2.2.4. Biodegradable polymers 
Cationic polymers containing predominantly –C–C–, vinyl or amide bonds in their 
backbone are not spontaneously degraded in aqueous solutions. This lack of 
biodegradability could create a problem following systemic applications in which the 
cationic gene carriers are not readily cleared from the body due to their large 
macromolecular structures, leading to their accumulation in cells and tissues where 
they potentiate further toxicity. Many cationic polymers with biodegradable main 
chains or side chains have since been designed and synthesized to overcome issues of 
cytotoxicity and to faciliate polyplex unpackaging to release free DNA in the cytosol 
[12, 59]. In general, these biodegradable cationic polymers are significantly less 
cytotoxic and they possess comparable or higher gene transfection efficiencies than 
the unmodified forms of cationic polymers such as PLL or PEI. Cationic polyesters 
represent the major class of biodegradable polymers employed for gene delivery. 
Poly(4-hydroxy-L-proline ester) (PHP) was the first biodegradable polycation 
reported for gene delivery by Langer’s [60] and Park’s [61] groups in 1999. It was 
shown that free PHP rapidly degraded to half of its intact molecular weight within 2 
hours in an aqueous solution of pH 7 at 37 °C mainly due to nucleophilic attack of its 
own ester linkage by the amines present in the monomers [61]. A slower degradation 
rate mediated by hydrolysis proceeds thereafter to result in near complete degradation 




least 4 hours at 37 °C, suggesting that the degradation rate of PHP is decreased 
presumably due to the unavailability of secondary amine groups on the polycations 
arising from their participation in electrostatic interactions with polyanionic DNA. 
The observed stability of the complexes effectively resulted in gene transfection 
efficiencies that were comparable to that of PLL.  
Poly[α-(4-aminobutyl)-L-glycolic acid] (PAGA) is a biodegradable polyester 
equivalent of PLL that is synthesized via the polymerization of modified Nε- 
carbobenzoxy (cbz)-L-lysine in which the α-amino group has been converted into a 
hydroxyl group, followed by the deprotection of the cbz groups [62]. Similar to PHP, 
the degradation of PAGA occurs very rapidly within 100 min to oligomers and then in 
a gradual manner to L-oxylysine monomers in 6 months in pH 7.3 HEPES buffer at 
37 °C [63]. In contrast to PLL/DNA complexes, biodegradable PAGA/DNA 
complexes (up to N/P 60) were less toxic and induced about 3-fold higher gene 
transfection efficiency in the presence of chloroquine. PAGA has been used to deliver 
plasmid DNA encoding for mouse interleukin 10 (mIL-10) via tail vein injection in 
non-obese diabetic (NOD) mice with promising results [64]. In this study, serum mIL-
10 levels peaked 5 days after injection with detectable levels persisting for more than 
9 weeks, which effectively reduced the prevalence of severe insulitis among the NOD 
mice. The synthesis of biodegradable poly(β-amino esters) via the conjugate addition 
of primary or secondary amines to diacrylates for gene delivery was first described by 
Langer et al. [65-70]. In the initial study, poly(β-amino esters) were found to degrade 
rapidly to give 1,4-butanediol and β-amino acids, with more rapid degradation 
occurring at pH 7.4 than at 5.1 [65]. The polymers and their degradation products 
were found to be non-toxic compared to PEI. The low cost of starting materials and 




polymer libraries of structurally diverse poly(β-amino esters) for the extensive 
screening, characterization, and analysis of structure-function relationships in 
polymer-mediated gene delivery [66-70].  
Another useful approach that has been widely adopted by researchers to obtain 
biodegradable polymers is through the introduction of reducible linkages within the 
polymer backbone. Conventional polycations such as PEI [71], lysine-containing 
peptides [72] and PAMAM [73-75] have been subjected to reversible crosslinking by 
disulfide bonds to overcome cytotoxicity issues associated with their respective higher 
molecular weight counterparts and to mediate intracellular uncoupling of DNA from 
complexes via reduction of disulfide linkages by glutathione, which is present at 
significantly higher concentrations within cells than in the extra-cellular physiological 
environments. In a recent study, biodegradable low molecular weight-based branched 
PAMAMs containing disulfide bonds synthesized via a one-pot, three-step method 
were demonstrated to have superior gene transfection efficiencies and lower 
cytotoxicities compared to PEI in several cell lines [74]. 
Poly(carbonates) are a relatively new class of biodegradable material used for 
therapeutic delivery. In contrast to the conventional polyester-based delivery systems 
such as poly(caprolactone), poly(lactide) and poly(adipic anhydride), the degradation 
of poly(carbonates) via hydrolysis and enzymatic degradation yields less detrimental 
acidic end products [76, 77]. This characteristic of poly(carbonates) is thus extremely 
desirable in gene delivery systems meant for systemic applications. Recently, He et al. 
synthesized low molecular weight PEI-grafted poly(carbonates) and demonstrated 
their enhanced gene transfection efficiencies and lower cytotoxicities compared to the 
high molecular weight PEI control, presumably due to the biodegradability of the 





1.3. Barriers limiting gene delivery and strategies adopted to overcome them 
It is crucial to understand various factors governing the success of gene delivery in 
order for a more effective approach to the modular design of non-viral vectors with 
high gene delivery efficiencies and good biocompatibilities. The major barriers to 
gene delivery have been identified to be (1) DNA packaging, (2) extracellular stability, 
(3) cellular uptake, (4) intracellular trafficking, (5) DNA unpackaging, and (6) 
biocompatibility (Figure 1.4). Due to the vast amount of information available for the 
different types of vectors, in this section, we will focus on the strategies employed in 
polymeric gene delivery systems for overcoming the various barriers.  
               
Figure 1.4. Barriers limiting gene delivery. Design requirements to develop efficient 
gene delivery systems include the ability to (I) package therapeutic genes; (II) ensure 
good cellular uptake and (III) mediate endosomal release of DNA; (IV) potentiate 
polyplex unpackaging leading to DNA release; (V) facilitate intracellular trafficking 
through the cytosol to enter the nucleus; and (VI) demonstrate good biocompatibility. 
Image reproduced with permission from [80]. Copyright (2007) Elsevier. 
 




As naked DNA are inherently prone to nuclease degradation and are lacking in 
efficiency to traverse cellular membranes, the successful sequestration and 
condensation of DNA by non-viral vectors into particles of appropriate size and 
charge constitutes an important first step to efficient gene delivery. The three main 
strategies that have been employed for DNA packaging include: electrostatic 
interactions, non-electrostatic interactions and encapsulation [22, 80, 81]. 
Spontaneous electrostatic interactions between polycationic vectors and polyanionic 
plasmid DNA are entropically driven and remain as the most dominant form of non-
viral vector/DNA interactions reported. Most cationic polymer systems incorporate 
primary, secondary, tertiary and/or quaternary amines which are protonated to various 
degrees at physiological pH. An optimal cationic vector nitrogen to DNA phosphate 
(N/P) charge ratio is essential for efficient DNA condensation and gene transfection. 
It is now established that a fine balance between DNA binding strength for initial 
DNA protection and the ability for competitive DNA release is important for efficient 
gene transcription and expression [12, 81]. Additionally, an excessive cationic charge 
in polycations and their resultant DNA complexes has been associated with 
unacceptable levels of cytotoxicity and hemolysis [82]. As such, researchers have 
introduced alternative gene packaging methods using neutral polymers such as 
polyvinyl pyrolidone [22] or lipopolythioureas [83-85] which may interact with DNA 
via hydrogen bonding and/or van der Waals interactions. DNA encapsulation involves 
the incorporation of naked DNA within a liposomal matrix or biodegradable 
polymeric scaffolds (e.g. polyesters) [80] that can shield the genetic material from the 
extracellular environment and mediate localized, controlled and/or sustained release 
of DNA [22]. This method has applications in tissue engineering as a useful approach 




differentiation or angiogenesis of cells. Some of the drawbacks of this method, 
however, include harsh preparation methods that involve the use of non-polar organic 
solvents, high shear stress and extreme pH and temperatures that could damage DNA. 
Other limitations include low encapsulation efficiency and low DNA bioavailability 
due to incomplete release of DNA or degradation of naked DNA upon release [80]. In 
order to overcome the latter problem, researchers have encapsulated DNA complexes 
into matrices.  
 
1.3.2. Extracellular stability  
As briefly mentioned earlier, the nature and strength of interaction between the 
vector and DNA has a direct influence on the physical, chemical and biological 
stability of the resultant DNA complexes. Upon introduction into the body, naked 
DNA molecules are exposed to a high concentration of nucleases that could lead to 
their degradation within minutes [81]. The packaging of DNA via binding and/or 
condensation by a gene vector serves to at least partially protect the DNA from rapid 
degradation by serum nucleases via steric hindrance. Colloidal instability is another 
pertinent issue adversely reducing the bioavailability of DNA complexes. Generally, 
polyplexes with net positive charges are more stable due to the presence of 
electrostatic repulsions between individual particles [12]. However, the high 
concentration of ions and negatively charged proteins such as serum albumin and 
glycosaminoglycans present in the physiological environment may exert a screening 
effect to weaken the electrostatic interactions between the cationic vector and DNA as 
well as reduce the interparticle electrostatic repulsive forces, eventually leading to the 
dissociation and/or aggregation of DNA complexes with time. Another potential 




serum proteins (opsonization) to DNA complexes that will predispose them to 
premature clearance by cells of the reticuloendothelial system.     
The conjugation or grafting of cationic polymers with 500 to 5000 Da PEG 
moieties is the most popular approach to improve the colloidal and serum stability as 
well as reduce the immunogenicity of cationic polyplexes [86]. The introduction of a 
PEG block permits the formation of a hydrophilic shield which prevents particle 
aggregation and opsonization via a reduction in the net surface charge and steric 
hindrance. While PEGylation is effective for enhancing polyplex stability and 
reducing immunogenicity, the charge shielding effect and steric hindrance conferred 
by PEG have been associated with a reduction in cellular uptake and gene transfection 
efficiencies [87]. Extensive research performed in this area has since demonstrated 
that the success of the PEGylation approach is contingent on the careful optimization 
of several factors such as PEG chain length and molecular architecture (e.g. block or 
graft) [87, 88]. Other hydrophilic moieties that have been employed to improve the 
colloidal stability of polycationic vectors include poly(methyl acrylate), poly(vinyl 
pyrrolidone) (PVP), and sugars (e.g. galactose, glucose and mannose) [12, 22, 23].  
    
1.3.3. Cellular uptake and endosomal escape 
At the cell surface, cationic polyplexes interact electrostatically with the anionic 
proteoglycans of the cell membrane and are taken up via non-specific adsorptive 
endocytosis. As a means to increase cellular uptake and confer cell specificity, 
targeting ligands are frequently incorporated in polymeric gene delivery systems by 
chemical conjugation [12, 89] or by electrostatic adsorption to positively charged 
polyplexes [90]. For most diseases involving a specific cell type, targeted delivery and 




overexpressed on certain cell populations has proven to be a useful strategy to 
augment therapeutic effects while limiting side effects. The enhanced cellular uptake 
provided by targeting moieties is also expected to enable a reduction in dose-
dependent cytotoxicities. Conventional targeting ligands utilized for gene delivery in 
cationic polymer systems are briefly summarized in Table 1.1 and they include 
carbohydrates, endogenous ligands, antibodies and peptides. Targeting rationale and 
strategies involving nanoparticles in various applications have been extensively 
reviewed elsewhere [89, 91, 92]. For the successful application of targeting 
approaches, various factors such as conjugation chemistry, degree of ligand 
substitution, spacer length between ligand and cationic segments, ligand-receptor 
affinity and ligand density per polyplex have to be carefully considered and optimized 
[12].  
 
Table 1.1. Targeting ligands utilized for cationic polymer-mediated gene delivery. 
Targeting ligand Target receptor Target cell type(s) Ref 
Carbohydrates:    
Galactose Asialoglycoprotein 
receptor 
Hepatocytes [93, 94] 
Mannose Mannose receptor Dendritic cells, 
macrophages 
[95] 
Glucose Glucose transporter Cancer cells [96] 
    
Endogenous 
ligands: 
   
Folate Folate receptor Cancer cells [97] 
Transferrin Transferrin receptor Cancer cells [45] 
    
















Cancer cells [99] 
    
Peptides:    
RGD Integrin receptor Endothelial cells [100, 101] 
EGF peptides Human epidermal 
growth factor 
receptor 
Cancer cells [102] 
HAIYPRH (T7) Transferrin receptor Cancer cells [55] 
 
Important endocytic pathways relevant in the cellular transport of macromolecules 
include phagocytosis, macropinocytosis, clarthrin-mediated endocytosis, caveolae-
mediated endocytosis, and clarthrin- and caveolae-independent endocytosis; of which 
the pathway employed is largely dependent on the size of the endocytic vesicle, nature 
of the cargo and the mechanism of vesicle formation [103]. The mode and extent of 
cellular internalization of DNA complexes varies with the type of vector [104, 105], 
size [106], and cell type [105]. Polyplexes are recognized to be primarily internalized 
via clathrin- and/or caveolae-dependent endocytic mechanisms [104, 105]. Unlike the 
caveolae-dependent pathway, the more well-characterized clathrin-dependent 
pathway is associated with the fusion of clathrin-coated pits with early endosomes 
with a concomitant fall in pH from neutral to ~ pH 6 in the endosomes [104, 107]. A 
further pH reduction to ~ pH 5 occurs during progression from late endosomes to 
lysosomes, where the enzymatic degradation of the polyplexes eventually occurs As 
such, intensive research efforts have been made to capitalize on the rapid pH 
reduction from neutral to acidic pH in the endosomes for the incorporation of 




on the use of pH sensitive moieties such as fusogenic peptides (e.g. KALA [108]), 
protonable amines (e.g. primary, secondary, tertiary amines, imidazole groups [24]) 
and alkylated carboxylic acid groups [109]. Fusogenic peptides undergo structural 
transition from a random coil at neutral pH to an α-helical conformation at the lower 
endosomal pH to mediate membrane interaction and disruption culminating in the 
release of endosomal contents. The intrinsically superior buffering capacities (via the 
proton sponge effect discussed earlier) conferred by the abundance of protonable 
amines in PEI [78, 79, 110] and PAMAM [75] have made them popular choices for 
the grafting or copolymerization with other neutral and biodegradable polymers in 
gene delivery applications. The alkylated carboxylic acids exert their buffering 
functions via the carboxyl groups while the hydrophobic alkyl groups serve to interact 
with the endosomal membrane for the subsequent disruption and release of endosomal 
contents [80]. A formulation of chitosan/DNA complexes with poly(propyl acrylic 
acid) (PPAA) was found to enhance the endosomal escape of the plasmid DNA [111]. 
It was found that the dose and sequence of PPAA addition affected the DNA release 
and transfection efficiency. 
 
1.3.4. Intracellular trafficking 
The exact mechanism of polyplex or DNA migration through the cytoplasm 
remains unclear. While it has shown that the diffusion of free DNA through the 
cytoplasm and nucleus is severely limited for fragments that are larger than 250 bp 
[112] and that the major barrier restricting the cytosolic transport of DNA lies with 
the dense network of actin cytoskeleton [113], the work by Vaughan and Dean [114] 
subsequently provided evidence that the DNA travels on the microtubule network to 




use of cytoskeletal modifying drugs, the authors demonstrated plasmid DNA 
molecules interact with the microtubules via the retrograde motor dynein and other 
cytosolic proteins to mediate DNA localization to the nucleus. To enhance nuclear 
localization of polyplexes or uncomplexed DNA, researchers have since utilized a 
wide array of nuclear localization signals, many of which are peptide sequences 
borrowed from viruses (e.g. SV40 and TAT) for conjugation to polymers or linear 
DNA molecules or for direct electrostatic complexation with DNA [115, 116]. These 
nuclear localization signals bind to cytosolic import proteins which aid in the active 
transport of the modified polyplexes or DNA through the nuclear pore complexes, 
which would otherwise preclude the passive diffusion of molecules larger than 9 nm 
or with molecular weight greater than 60 kDa [117]. The effectiveness of this strategy, 
however, remains controversial as no discernible improvements in gene transfection 
efficiencies have been reported in some studies [118]. The transfection efficiency of 
polyplexes has also been shown to be cell cycle-dependent, with high levels of gene 
expression observed when the transfection is performed shortly before the mitotic 
phase (i.e. S and G2 phases) [119, 120]. This phenomenon has been attributed to the 
transient breakdown in nuclear membrane during cell division, which allows the DNA 
or polyplexes to gain entry into the nucleus. However, it remains to be seen if this 
feature can be exploited for enhancing polyplex-mediated gene delivery especially 
when many cell types in the body are non-dividing and vector-dependency has been 
observed [121]. 
 
1.3.5. DNA unpackaging 
The competitive displacement of DNA molecules by anionic membrane lipids, 




mechanism for the intracellular release of DNA from polyplexes, although the exact 
mechanism and location of DNA unpackaging remains unclear [12, 23, 80]. As such, 
over-stabilized electrostatic interactions between the highly charged polycations and 
DNA may be a potential barrier for efficient gene expression. As discussed earlier, a 
precise balance between DNA protection and release from polyplexes is crucial to 
obtain good gene transfection efficiencies. Many biodegradable or stimuli-responsive 
polymers have significant advantages to mediate DNA release from polyplexes in a 
time- and location-specific manner. Other factors such as polymer length, charge 
density and polymer structure have also been found to influence the DNA protection 
and release capabilities of cationic polymers. A comprehensive review on this topic 
has been provided  by Grigsby et al. [122]. In the case of biodegradable polycations, a 
higher concentration or N/P ratio has been observed to be required for mediating 
efficient gene transfection compared to controls, suggesting that more polymers are 
required to execute the gene transfection processes (e.g. DNA protection, cellular 
uptake) in order to compensate for their rapid degradation. As such, efforts have to be 
made to understand and tailor the degradation kinetics of biodegradable polymers to 
ensure adequate time to perform their DNA protection function prior to cellular 
uptake and nuclear entry of DNA.  
 
1.3.6. Biocompatibility 
Besides high transfection efficiencies and favorable physicochemical properties, an 
important prerequisite for the successful clinical application of gene delivery vectors 
is good biocompatitility. Conventional synthetic cationic polymers such as PEI, PLL 
and PAMAM dendrimers have been found to induce significant hemolysis and 




as size and charge-dependent manner. The high charge densities of these cationic 
polymeric carriers have been identified as the major cause behind cellular membrane 
damage and phospholipid reshuffling, which often leads to the activation of the 
apoptotic or necrotic pathways [123]. Additionally, complement activation has also 
been identified as a major problem that is strongly dependent on the molecular weight, 
polycation length, charge density and dose of cationic polymers [124, 125]. The 
activation of complements initiates a biochemical cascade that results in the 
premature clearance of the foreign particles by phagocytes and alters cellular 
immunity by enhancing B-cell responses and dendritic cells and T cells activation 
[82]. While this activity may be desirable on a local scale for improved antigen 
presentation for vaccines, it is undesirable for most systemic applications of 
polycation-based gene carriers as it may precipitate life-threatening hypersensitivity 
reactions.  
In efforts to overcome potential cytotoxicity, hemolysis and immune activation, the 
charge shielding effects of hydrophilic moieties such as PEG, PVP and carbohydrates 
have been extensively exploited in the design of cationic polymers for systemic gene 
delivery. As discussed earlier, the incorporation of PEG has an added benefit for 
enhancing the overall stability of DNA complexes. In a study by Liu et al.,  an 
optimized biodegradable hyper-branched PEI (25 kDa)-grafted polycaprolactone (570 
Da)-block-mono-methoxyl poly(ethylene glycol) (2kDa) copolymer (hy-PEI25k-g-
PCL570-b-mPEG2k) was found to exhibit less toxicity in the A549 cell line and to 
induce less hemolysis compared to the 25 kDa PEI control [126]. This study, together 
with many others, has also demonstrated that the use of biodegradable polymers is an 
effective strategy to lower the cytotoxicities of gene delivery systems, presumably due 




polycation degradation. In another recent study, Merkel et al. demonstrated that 
branched PEI(25kDa)-PEG(20kDa) block copolymer displayed negligible in vitro 
complement activation and significantly less hypersensitivity responses in pig models 
compared to unmodified PEI [125]. As the adverse reactions described here are dose-
dependent, the incorporation of targeting ligands in cationic polymers as highlighted 
in Section 1.3.3 is also expected to enhance biocompatibility as the enhanced cellular 
uptake of DNA complexes is likely to permit a reduction in the amount of polycation 
used.  
 
1.4. Summary and Concluding remarks 
As seen from this Chapter, synthetic non-viral vectors possess significant 
advantages over their viral counterparts as the wealth of well-established synthetic 
chemistries has allowed for the large-scale and cost-effective preparations of well-
defined chemical entities for gene delivery. The lower immunogenic and carcinogenic 
risks of non-viral vectors are also a major advantage. Unlike with the viral vectors, 
there is theoretically no restriction on the size of gene delivered by non-viral vectors. 
Among the classes of non-viral vectors, cationic polymers are highly attractive for 
gene delivery due to their relatively facile synthesis and greater synthetic versatility to 
precisely tailor functional groups (e.g. ligands for cellular targeting or stimuli-
sensitive elements) to meet the specific needs of each application. Generally, cationic 
polymers also offer a more convenient direct dissolution and self-assembly approach 
to obtain polyplexes in aqueous solutions. In a recent review by Mintzer and Simanek, 
it was reported that several polymeric vectors based on PEI and PLL have been used 
in phase 1 or 2 clinical trials for the treatment of cystic fibrosis, cancers and human 




trials involving the conventional or ‘first generation off-the-shelf’ polymeric vectors 
hold great significance on several fronts; firstly, they provide evidence for the safety 
and effectiveness of cationic polymers in clinical applications and secondly, they 
provide strong impetus for the continued development and clinical evaluations of 
innovative polymeric gene delivery systems. As the newer generation of carriers has 
been designed using guiding principles for overcoming the various gene delivery 
barriers in mind, they are expected to be safer and more effective than their 
predecessors. Recently, biodegradable polymers have emerged as highly attractive 
candidates for use in gene delivery as they have the advantages of reducing long term 
accumulations in the body following repeated administrations and facilitating 
intracellular DNA release. However, in order to achieve favorable and predictable 
pharmacological profiles, it is imperative that the synthetic method employed is 
biofriendly and allows for good control over molecular weight distributions. The 
recent advancements made in synthetic methodologies such as metal-free 
organocatalytic ring-opening polymerization have provided tremendous opportunities 
to synthesize multifunctional polymers that are well-equipped to overcome the 
barriers limiting successful gene delivery. With extensive efforts made to design 
synthetic polymeric gene carriers with improved gene transfection efficiencies and 
good biocompatibilities, widespread gene therapy of various genetic and acquired 




CHAPTER 2. Hypothesis and Aims 
 
The lack of safe and efficacious gene delivery vectors has critically impeded the 
clinical advancement of gene therapy. As discussed in Chapter 1, non-viral synthetic 
polymers are excellent options as gene carriers due to the synthetic ease of 
incorporating numerous functional moieties while ensuring biocompatibility, stability 
and reproducibility. Aliphatic polycarbonates are fast emerging as a highly valuable 
class of biomaterials due to their inherent biocompatibility, biodegradability, facile 
synthesis, and ease of tailoring functionalities to meet specific requirements of various 
applications. Although they have been extensively studied as drug carriers [128-133], 
their applications in gene delivery are limited to a few independent studies [78, 79, 
110, 134, 135]. Therefore, there lies great potential and scope to exploit this 
remarkably versatile class of material for the development of effective gene carriers. 
The overall goal of this thesis is thus to design and evaluate a novel class of 
biodegradable cationic polycarbonates and their copolymers for their safety and 
efficacy in gene delivery.  
We hypothesized that cationic polycarbonates with well-controlled molecular 
weights and narrow polydispersities imparted by metal-free living organocatalytic 
ROP of functionalized cyclic carbonate monomers, followed by a subsequent 
quaternization reaction with bis-tertiary amines, are safe and effective as gene carriers. 
Our hypothesis was based upon several observations and insights made from the few 
existing polycarbonate-based gene delivery systems reported in the literature. Firstly, 
linear low molecular weight poly(ethyleneimine) (PEI)-grafted polycarbonates [78, 
79] and poly(ethylene glycol) (PEG)-b-poly(carbonates-g-oligoethylenimine) [110] 




higher gene transfection efficiencies and lower cytotoxicities compared to the higher 
molecular weight 25 kDa PEI. However, the polydispersity indices (PDIs) of these 
PEI-grafted polycarbonates, particularly with the higher molecular weight polymers, 
were found to be relatively large (ranging from 1.2–1.7), which may indicate limited 
polymerization control. Moreover, the presence of residual Zn catalysts in the latter 
study also raises concerns about potential toxicity issues. These studies have provided 
in vitro evidence for the efficacy and biocompatibility of cationic polycarbonates for 
gene delivery, but more efficient and biofriendly synthetic methods are required to 
enhance the in vivo applicability of functional polycarbonates. It is crucial for a 
delivery system to be structurally well-defined and to possess a narrow molecular 
weight distribution as different molecular weight fractions are expected to exhibit 
distinct pharmacological properties in vivo [123]. In another study, polycarbonates 
bearing pendant primary and secondary amines prepared via metal-free living 
organocatalytic ROP [136], in contrast, were shown to possess very narrow molecular 
weight distributions (PDI < 1.2) and could efficiently induce gene expression that was 
comparable or superior to PEI with minimal cytotoxicities [134]. The results of this 
study provide direct evidence that organocatalytic ROP is an extremely efficient 
method that offers good polymerization control to yield well-defined and narrowly 
dispersed polycarbonates for gene delivery. However, certain inadequacies such as the 
requirement for high concentration of polymers to mediate effective gene transfection 
and large particle sizes (200 to 1000 nm) of the resultant polycarbonate/DNA 
complexes remain. Further modifications are necessary to increase the polycarbonate 
charge densities to improve the DNA binding and condensation abilities for the 






To test our hypothesis, we explored three specific aims: 
(1) Rationally design and evaluate the gene transfection ability and cytotoxicity of 
novel cationic polycarbonates bearing quaternary and tertiary amines in the 
side chains. 
(2) Enhance the stability of DNA complexes through the use of block copolymers 
of poly(ethylene glycol) (PEG) and cationic polycarbonates; and investigate the 
effects of PEG configuration within block copolymers on key aspects of gene 
delivery. 
(3) Examine the efficacy of galactose-functionalized polycarbonate block 
copolymer for targeted gene delivery to hepatocytes. 
 
Work performed to address each specific aim is as outlined in the following 
chapters: In Chapter 3, we provided an important in vitro proof-of-concept for the 
gene transfection efficiency and biocompatibility of a novel cationic polycarbonate 
bearing quaternary and tertiary amines in the pendant chains (Aim 1). In Chapter 4, 
we designed block copolymers of PEG and cationic polycarbonates to capitalize on 
the favorable properties of the PEG macroinitiator for potential in vivo applications. 
The effects of PEG configuration within block copolymers on key aspects of gene 
delivery was investigated for the first time (Aim 2). In Chapter 5, a galactose-
functionalized cationic polycarbonate block copolymer was designed to mediate 
active targeting of DNA to the asialoglycoprotein receptor-expressing hepatocytes 
(Aim 3). Lastly, in Chapter 6, we provided a conclusion and our perspectives for 




The successful completion of this thesis has evidently established the molecularly 
well-defined and narrowly dispersed cationic polycarbonates and their copolymers 
prepared by organocatalytic ROP as safe and efficient non-viral gene carriers. The 
promising findings presented here should provide the impetus for further preclinical 
evaluations of cationic polycarbonates and their copolymers for gene delivery.  
35 
 
CHAPTER 3. Rational design of cationic polycarbonate for in vitro gene delivery 
 
3.1. Background 
As mentioned in Chapter 1, the bottleneck to realizing the tremendous potential of 
gene therapy for medical applications lies with the lack of a safe and efficacious 
vector that can package and protect the genetic material in extracellular environments 
and penetrate the cell to readily release its genetic cargoes. In recent years, well-
defined synthetic transporters are increasingly drawing attention as promising 
alternatives to viral vectors. These non-viral vectors not only cost less to produce, but 
also possess highly tunable functionalities and molecular architectures to fulfil various 
requirements critical for efficient gene delivery [8, 12, 92]. Of the various synthetic 
materials available, poly(ethylenimine) (PEI) is arguably one of the best in terms of in 
vitro gene transfection efficiencies, which can be attributed to its high positive charge 
density for DNA compaction and delivery as well as the unique proton sponge 
properties conferred by the high density of secondary and tertiary amines that 
participate in the endosomal buffering process, hence facilitating the liberation of 
DNA into the cytoplasm [8, 12, 32, 137]. Its clinical potential, however, has been 
drastically limited by its non-biodegradability and high cytotoxicity. A new 
generation of biodegradable cationic polymers has since been synthesized to 
overcome the two important barriers to efficient gene delivery – polyplex 
unpackaging and cytotoxicity [8, 12, 115]. Despite having been demonstrated to be 
somewhat less toxic, with comparable, or superior, gene transfection efficiencies to 
PEI, various examples including poly(β-amino esters) (PBAEs) [138, 139], modified 
PEIs [79, 140], and dendrimers based on poly(amido amine) (PAMAM) [141-144] 




large polydispersities, complex molecular architectures, multiple production steps and 
high cost of starting materials (in the case of amino acids). A narrow molecular 
weight system is crucial in the clinical settings as individual molecular weight 
fractions of a polydisperse system are expected to exhibit distinct pharmacological 
activities in vivo [123]. Therefore, the quest for novel materials with uncomplicated 
synthetic schemes, well-controlled molecular weights and narrow polydispersities for 
potential clinical gene therapy applications continues.  
Aliphatic polyesters and polycarbonates are a class of biomaterials that have been 
studied extensively in various biomedical applications due to their highly tunable 
mechanical properties, biocompatibility, low toxicity and biodegradability via 
hydrolysis in vivo [146-148]. However, conventional synthetic methods to prepare 
functionalized lactone and carbonate monomers are not practical due to instability of 
the monomers, multiple synthetic steps, low yield, and expensive starting materials 
[149-151]. To address these issues, a broadly applicable synthetic approach to 
functional cyclic carbonate monomers using an inexpensive biocompatible synthon, 
bis(2,2-hydroxymethyl)propionic acid (bis-MPA), as a starting material have been 
developed [152]. It was demonstrated that functional carbonate-based polymers can 
be synthesized by metal-free organocatalytic living ring-opening polymerization, and 
are applicable in medicine as carriers for delivery of small molecular therapeutics 
[129, 153, 154]. In the area of gene delivery, the use of carbonate-based polymers has 
been less widely documented. Therefore, this versatile class of synthetic polymer 





Recently, R.X. Zhuo’s team has reported polyethylenimine-grafted polycarbonates, 
which induced high gene transfection in 293T cells at high polymer concentrations 
while causing little cytotoxicity [79]. The polyethylenimine-grafted polycarbonates 
were synthesized through three steps: firstly, polycarbonates with pendant 
allyloxycarbonyl groups were obtained by enzymatic ring-opening polymerization, 
and subsequently functionalized with epoxy groups. Low molecular weight PEI 
residues were then grafted onto the polycarbonate via the epoxy groups. Our group 
has also successfully synthesized amine-functionalized polycarbonates by a different 
synthetic approach, i.e. organocatalytic ring opening polymerization, and utilized 
these amine-functionalized polycarbonates as gene delivery vectors that were capable 
of inducing efficient gene transfection in HEK293, 4T1 and HepG2 cell lines [134]. 
The particle sizes of these polycarbonate-DNA complexes, however, were found to be 
large and were in the range of approximately 200 to more than 1000 nm, suggesting 
inefficient condensation of DNA. Moreover, the high gene transfection efficiencies 
were obtained only at very high polymer concentrations (or N/P ratios). While the 
polycarbonates were demonstrated to have little adverse effects on cellular toxicity in 
vitro, the large particle sizes coupled with the requirement for high polymer 
concentrations could unfavorably affect gene transfection in vivo.  
Therefore, in order to further improve on the current models of polycarbonate-
based gene delivery vectors novel cationic polycarbonates were prepared by two steps, 
i.e. organocatalytic ring-opening polymerization (ROP) of cyclic carbonate monomers 
with alkyl halide side chains to generate narrowly dispersed polymers with exquisite 
control over their molecular weights, followed by quaternization with bis-tertiary 
amines. This chapter is thus focused on the systematic evaluation of the novel cationic 




ammoniums for electrostatic condensation of the negatively charged DNA into 
slightly positively charged nanoparticles, which are known to enhance cellular uptake 
by endocytosis [32, 155], as well as tertiary amines to provide the buffering capacity 
required for the endosomal escape [75, 156] of the polycarbonate-DNA into the 
cytoplasm where the genetic cargo will be released (Scheme 3.1). DNA binding and 
biophysical (particle size and zeta potential) properties of the polycarbonate, together 
with the gene transfection capabilities and cytotoxicities in human hepatocellular 
carcinoma cell line, HepG2, human embryonic kidney cell line, HEK293, human 
mammary cancer cell line, MCF-7, and mouse mammary cancer cell line, 4T1, were 
evaluated in comparison with the commercially available PEI standard. 
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Scheme 3.1. Key design features of cationic polycarbonate for gene delivery. 
 





Sodium dihydrogen phosphate, disodium hydrogen phosphate, poly(ethyleneimine) 
(PEI; branched, Mw = 25 kDa), heparin sodium salt and 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) were all purchased from Sigma-Aldrich and 
used as received. Ultra pure (HPLC grade) water was obtained from J.T. Baker 
(U.S.A.). Phosphate-buffered saline (PBS) and tris-borate-EDTA (TBE) buffers were 
purchased from 1st BASE (Singapore) and diluted to the intended concentrations 
before use. 1 kb DNA ladder was purchased from New England Biolabs, while 
ethidium bromide solution was obtained from Biorad Laboratories (U.S.A.). RQ1 
RNase-free DNase, reporter lysis buffer and luciferin substrate were purchased from 
Promega (U.S.A.) and bicinchoninic acid (BCA) protein assay reagent was purchased 
from Pierce (U.S.A.). Plasmid DNA encoding the 6.4 kb firefly luciferase gene driven 
by the cytomegalovirus (CMV) promoter was obtained from Carl Wheeler, Vical 
(U.S.A.), amplified in Escherichia coli DH5α and purified using Endofree Giga 
plasmid purification kit from Qiagen. Ultrapure agarose, minimum essential medium 
(MEM), Dulbecco’s modified eagle medium (DMEM) and RPMI-1640 growth 
media, fetal bovine serum (FBS), sodium pyruvate, non-essential amino acids, 
penicillin and streptomycin were all purchased from Invitrogen (U.S.A.). HepG2, 
HEK293, MCF-7 and 4T1 cell lines were purchased from ATCC (U.S.A.) and 
cultivated under the recommended conditions.  
 
3.2.2.  Synthesis and Characterization of Cationic Polycarbonates   
Functionalized methylcarboxytrimethylene carbonate (MTC) monomers and 
cationic polycarbonates used in this study were synthesized by Dr Kazuki Fukushima 




characterization of MTC monomers and polymers are found in Appendix A and in our 
previous publications [152, 153].  
 
3.2.3. Preparation of Cationic Polycarbonate 3d or PEI/DNA Complexes 
The polycarbonate 3d and PEI were first dissolved in 10 mM phosphate buffer (pH 
6.0) and HPLC grade water respectively. To form the complexes, equivolume solution 
of DNA was dripped into polycarbonate 3d or PEI to achieve the intended N/P (molar 
ratio of N content in the polymer to the DNA phosphorus content) ratios under gentle 
vortexing for ~10s. The mixture was equilibrated at room temperature for 30 min to 
allow for complete electrostatic interaction between the polycarbonate 3d/PEI and the 
DNA molecules, before being used for subsequent studies.  
 
3.2.4. Gel Retardation Assay 
Various formulations of polycarbonate 3d/DNA complexes were prepared with 
N/P ratios ranging from 0.6 to 9. Post-equilibration, the complexes were 
electrophoresed on 0.7% agarose gel (stained with 5 μL of 10 mg/mL ethidium 
bromide per 50 mL of agarose solution) in 0.5× TBE buffer at 80V for 50 min. The 
gel was then analyzed under an UV illuminator (Chemi Genius, Evolve, Singapore) to 
reveal the relative position of the complexed DNA to the naked DNA. 
 
3.2.5. Particle Size and Zeta Potential Measurement 
The particle sizes and zeta potentials of the post-equilibrated polycarbonate 3d and 
PEI/DNA complexes with or without 11 × dilution with 1 × PBS (pH 7.2) were 
measured by dynamic light scattering (Brookhaven Instrument Corp., Holtsville, NY) 




Zetasizer (Malvern Instrument Ltd., Worcestershire, UK) respectively. Particle size 
and zeta potential measurements were repeated for 3 runs per sample and reported as 
the mean ± standard deviation of 3 readings. 
 
3.2.6. Heparin Displacement Assay 
Polycarbonate 3d/DNA complexes were first formed at N/P ratio 12 and then 
incubated with equivolumes of heparin (final concentration ranged from 0.1 to 20 
mg/mL) dissolved in 10 mM phosphate buffer (pH 6.0) for 1 h at room temperature. 
DNA released by heparin treatment was analyzed by agarose gel electrophoresis with 
ethidium bromide staining. The experiment was also performed with PEI/DNA 
complexes formed at N/P ratio 10, followed by treatment with equivolumes of heparin 
dissolved in HPLC grade water for the same duration of time.  
 
3.2.7. Nuclease Degradation Assay 
17 μL of free DNA (0.85 μg) or polycarbonate 3d/DNA complexes formed at N/P 
ratios 3, 6 and 12 were each incubated with 2 μL of 10 × Reaction Buffer and 1 μL of 
DNase 1 (1 U/ μL) at 37 °C. At appropriate time points (10, 30 and 60 min), the 
DNase was inactivated by adding 2 μL of Stop Solution followed by incubating the 
respective tubes at 65 °C for 10 min. To displace the bound DNA, 5 μL of 10 mg/ml 
heparin solution was added and the tubes were further incubated for 1 h at room 
temperature before the DNA samples were separated using agarose gel 
electrophoresis.  
 




HepG2 and HEK293 cells were maintained in MEM and DMEM growth medium 
respectively, while MCF-7 and 4T1 cells were cultured in RPMI-1640 growth 
medium. All growth media used were supplemented with 10% FBS, 1 mM sodium 
pyruvate, 100 U/mL penicillin and 100 mg/mL streptomycin and cultured at 37oC, 
under an atmosphere of 5% CO2 and 95% humidified air. The reporter gene used was 
the 6.4 kb firefly luciferase gene driven by the cytomegalovirus (CMV) promoter 
(Carl Wheeler, Vical, U.S.A.). 
The in vitro gene transfection efficiency of the cationic polycarbonate 3d or 
PEI/DNA complexes was investigated using HepG2, HEK293, MCF-7 and 4T1 cell 
lines. Cells were seeded onto 24-well plates at a density of 8 × 104, 8 × 104, 1.4 × 105 
and 5 × 104 cells per well respectively. After 24 h, the plating media was replaced 
with 0.5 mL of fresh growth media (containing 10% FBS), followed by the addition 
of 50 μL of complex solution (containing 2.5 μg DNA). Following 4 h of incubation, 
free complexes were removed by replacing the media in each well. After a further 68 
h of incubation, the cell culture media in each well were removed and the cells rinsed 
once with 0.5 mL of PBS before 0.2 mL of reporter lysis buffer was added to each 
well. The cell lysate collected after two cycles of freezing (-80 °C, 30 min) and 
thawing was cleared by centrifugation at 14 000 rpm for 5 min, after which, 20 μL of 
supernatant was mixed with 100 μL of luciferase substrate for the determination of 
relative light units (RLU) using a luminometer (Lumat LB9507, Berthold, Germany). 
The RLU readings were normalized against the protein concentration of the 
supernatant determined using the BCA protein assay to give the overall luciferase 
expression efficiency. In all in vitro gene expression experiments, naked DNA was 




(i.e. 10), at which PEI induced high gene expression efficiency yet provided close to 
or more than 50% cell viability, were used as the positive control. Data are expressed 
as mean ± standard deviations of four replicates. 
 
3.2.9. MTT Test 
The cytotoxicity of the polycarbonate 3d/DNA complexes was studied using the 
standard MTT assay protocol. Briefly, HepG2, HEK293, MCF-7 and 4T1 cells were 
seeded onto 96-well plates at densities of 10 000, 8000, 15 000 and 6000 cells per 
well respectively and allowed to grow to 60-70% confluency before treatment. 
Polycarbonate 3d/DNA complexes at N/P ratios of 3, 6, 12, 18, 24 and 29 were 
prepared in 10 mM phosphate buffer (pH 6.0) as described earlier. The cells in each 
well were then incubated with sample-containing growth media comprising of 10 μL 
of polycarbonate 3d/DNA complexes and 100 μL fresh media for 4 h at 37 oC. 
Following incubation, the wells were replaced with fresh growth media and incubated 
further for 68 h. Subsequently, 100 μL of growth media and 10 μL of MTT solution 
(5 mg/ml in PBS) were then added to each well and the cells were incubated for 4 h at 
37 oC according to the manufacturer’s directions. Resultant formazan crystals formed 
in each well were solubilized using 150 μL of DMSO upon removal of growth media. 
A 100 μL aliquot from each well was then transferred to a new 96-well plate for 
determination of absorbance using a microplate spectrophotometer at wavelengths of 
550 nm and 690 nm. Relative cell viability was expressed as [(A550-A690)sample/(A550-
A690)control] × 100%. Data are expressed as mean ± standard deviations of at least eight 





3.3. Results and Discussion 
3.3.1. Polymer Synthesis and Characterization 
Scheme 3.2 summarizes the general synthetic methods for preparation of the 
cationic polycarbonates. The synthesis of the alkyl halide functional carbonate 
monomer was accomplished by tagging the appropriate haloalkyl alcohols on the 
cyclic carbonate ring via a simple transesterification reaction. All haloalkyl 
functionalized MTC monomers were crystalline and easily purified by either 
recrystallization or by flash chromatography (ethyl acetate/hexane) in good yields. 
The ROP was conducted using BnMPA as a difunctional initiator in the presence of 
organocatalysts, TU and DBU, in methylene chloride at room temperature for 2 h to 
yield the precursor polymers 2 with molecular weights consistent with the monomer-
to-initiator feed ratios ([M]0/[I]0), narrow polydispersities (1.1 – 1.2), and end group 
fidelity (Table 3.1). To avoid scission of polymer by transesterification caused from 
the terminal hydroxyl group in the presence of amine during the subsequent 
quaternization, the precursor polymers were acetylated with acetic anhydride. Then 
the precursors were quaternized by TMEDA in DMSO to provide the corresponding 
cationic polymers. Although it can be anticipated that crosslinking might occur 
between TMEDA and haloalkyl side chains, excess of the reagent mitigates this 
concern [157]. The reactivity of the precursor polymers with TMEDA depends on this 
halogen substituent on the side chain.  For example, 2a had to be heated at 90 °C for 
quaternization to give 3a whereas 2b and 2c were easily converted to the 
corresponding cationic polymers 3b and 3c at room temperature. However, it was 
hard to quantitatively quaternize any homopolymers 2a-2c probably due to the 
reaction equilibrium and increased steric hindrance of the side chain at the late stage 




tertiary amine at the end of the quaternized side chain after the polymer was isolated, 
even in the presence of surplus reagent. Polymer 3a showed no gel formation, likely 
because of the low reactivity of chlorine, whereas 3b and 3c included a small amount 
of insoluble material. In addition, iodine of 2c seemed to be highly reactive, resulting 
in difficulty in handling and formation of more crosslinked material. In light of these 
results, 1b was the preferred functional precursor to the desired gene carrier in terms 
of reasonable reactivity, stability and ability to prepare a random copolymer 2d with 
monomer 1d as a spacer for dilution of the charge. No crosslinking was observed in 
the cationic polymer 3d even at quantitatively quaternization, which further suggests 
that sterics influence the reaction conversion with the spacer 1d randomly 
incorporated in the polymer chain. Even though 50% of 3d consists of hydrophobic 
monomer 1d, the polymer showed good solubility in water, suggesting that the 
quaternary ammonium and tertiary amine on a side chain significantly contribute to 
the hydrophilic nature of the polymer. To this end, we focused on 3d to form DNA 






Scheme 3.2. Synthesis of cationic polycarbonates. (i) BnMPA, TU (0.025 eq.), DBU 
(0.025 eq.), CH2Cl2, RT, 2 h, [M] = 1.0 M. (ii) Ac2O, RT, 2 nights. (iii) TMEDA (4 
eq.), DMSO, 6 h at 90 °C or overnight at RT. 
 
Table 3.1.  Characteristic data of precursor and cationic polycarbonates  
precursor    charged    
 Mn a 
(g/mol) 
PDI a Yield 
(%) 






2a 12200 1.17 93 3a 13900 86 85 
2b 11700 1.11 92 3b 17500 88 93 
2c 10500 1.22 86 3c 17400 77 90 
2d 11400 1.20 77 3d 15300 90 ~100 
a Determined by GPC (THF) using polystyrene standards.  b Calculated from 






3.3.2. DNA binding ability 
As DNA binding by a gene delivery vector constitutes an important first step for 
the formation of stable and compact DNA complexes that are essential for efficient 
cellular uptake [12, 59, 115], we first evaluated DNA binding efficiency of the 
polycarbonate 3d using the gel retardation assay. Figure 3.1 shows that the cationic 
polycarbonate was able to bind to and condense DNA from N/P ratio 0.6. The degree 
of DNA binding and hence the retardation of its movement across the agarose gel was 
enhanced with increasing concentrations of the cationic polycarbonate, giving rise to 
complete retardation of DNA movement at N/P ratio 2.3. PEI, on the other hand, gave 
rise to complete retardation of DNA from N/P ratio 3. 
 
Figure 3.1. Electrophoretic mobility of DNA in 3d/DNA and PEI/DNA complexes. 
 
3.3.3. Size and Zeta-potential Analyses 
Consistent with the efficient DNA condensation demonstrated, electrostatic 
interactions between the cationic polycarbonate and anionic DNA led to the formation 
of compact complexes with small hydrodynamic sizes in the range of 83 to 124 nm in 
10 mM phosphate buffer (pH 6.0) (Figure 3.2) at the N/P ratios tested. The size 
distribution of the complexes was found to be narrow with polydispersities below 0.2. 
DNA complexes formed with PEI, shown extensively to confer high gene transfection 
3d/DNA 
N/P ratios 









efficiencies in various cell lines [32, 137, 158], on the other hand, were found to have 
a hydrodynamic size of 206 nm. PEI complexes were formulated at N/P ratio 10 in 
HPLC grade water in all our studies as such a formulation has been demonstrated in 
our lab to provide high gene transfection efficiencies, with more than 50% cell 
viability at the end of the transfection experiments. These results showed that 
polycarbonate 3d was able to condense the negatively charged DNA molecules to 
form nano-sized particles in solution. 



























Figure 3.2. Effective mean diameter (column) and zeta-potentials (line) of 3d/DNA 
complexes at the various N/P ratios specified. PEI/DNA complexes were prepared at 
N/P ratio 10. 
 
The surface charge of gene delivery vectors plays a pivotal role in determining 
gene transfection efficiency [12, 59, 115]. Extensive studies have demonstrated that 
DNA condensation and stabilization are enhanced when a carrier possesses a positive 
surface charge [12, 115]. In addition, a net positive charge on the surface of 
carrier/DNA complexes is favorable for effective cellular uptake via electrostatic 
interactions with the negatively charged phospholipid surface of the cell membrane. 
Indeed, the cationic polycarbonate interacted electrostatically with the anionc DNA to 




mM phosphate buffer (pH 6.0) from N/P ratio 6 onwards (Figure 3.2). The zeta-
potentials of the polycarbonate/DNA complexes were found to be higher than the 19.6 
± 0.2 mV obtained with PEI/DNA formulated at N/P ratio 10.  
 
3.3.4. Heparin Displacement Assay 
As discussed under Introduction, a delicate balance must be achieved in the degree 
of electrostatic interaction between cationic gene delivery vectors and DNA such that 
initial DNA binding and protection is provided, while subsequent competitive 
dissociation and release of DNA from the complexes can be achieved following 
cellular uptake [8, 12]. We next investigated the binding strength of the polycarbonate 
3d/DNA complexes by treating pre-formed complexes at N/P ratio 12 to various 
concentrations of heparin, a negatively charged molecule known to disrupt DNA 
interactions [159], for 1 h. Displaced DNA was visualized by agarose gel 
electrophoresis, with ethidium bromide staining. DNA still bound to the 
polycarbonate will either be seen in the loading well or not be visible due to the 
inability of ethidium bromide to intercalate condensed DNA. As shown in Figure 3.3, 
a slightly higher degree of DNA displacement from the polycarbonate/DNA 
complexes was observed at 0.1 mg/mL heparin concentration compared to the 
PEI/DNA complexes. This result suggests that PEI binds more tightly to DNA 
compared to the polycarbonate. Complete displacement of DNA from the 
polycarbonate 3d/DNA complexes was obtained between heparin concentrations of 
0.1-1 mg/mL. This result provides direct evidence that the DNA can be efficiently 
released from polycarbonate/DNA complexes via competitive displacement with 




    
 
Figure 3.3. Heparin displacement assay with 3d or PEI/DNA complexes incubated 
with increasing concentrations of heparin for 1 h at room temperature. 
 
3.3.5. DNase Protection Ability 
Under physiological conditions, foreign DNA is subjected to rapid enzymatic 
degradation by nucleases present in the bloodstream and cellular cytoplasm. Thus, it 
is imperative for a gene delivery vector to protect its genetic cargo from nuclease 
degradation. This property has been directly correlated with the DNA binding strength 
of the gene delivery vector in the literature [160, 161]. To determine whether 
polycarbonate 3d can protect DNA from enzymatic degradation, polycarbonate 
3d/DNA complexes formed at N/P ratios 3, 6 and 12 were incubated with DNase 1, 
an endonuclease that catalyzes the degradation of DNA to di-, tri-, and 
oligonucleotides [161], for specific periods of time, and the integrity of the DNA was 
visualized by agarose gel electrophoresis after competitive displacement of DNA 
molecules from the complexes using heparin. The final concentration of heparin 
employed in this experiment was 1.85 mg/ml, which was above the minimum 
concentration required for complete DNA displacement from polycarbonate 3d/DNA 
complexes as determined from Figure 3.3. The same amount of naked DNA was 
treated with DNase 1 for 10 min as a control. As illustrated in Figure 3.4, complete 
PEI (N/P 10) 3d (N/P 12) 




degradation of DNA was observed within 10 min treatment with DNase 1. In contrast, 
a portion of the circular (upper) and supercoiled (lower) bands of plasmid DNA from 
the polycarbonate 3d/DNA complexes was preserved across all three N/P ratios tested 
up to 10 min, clearly indicating the ability of the gene delivery vector to protect DNA 
from DNase 1 degradation. The additional band observed between the circular and 
supercoiled bands of undegraded DNA in polycarbonate 3d/DNA complexes treated 
with DNase 1 possibly corresponds to linear DNA chains produced by enzymatic 
cleavage of both circular and supercoiled DNA molecules [161]. Linear DNA chains 
are then further degraded into smaller fragments, which collectively appear as a smear 
on the ethidium bromide-stained agarose gel. At a low N/P ratio of 3, a significant 
decrease in the band intensities was observed after 30 min incubation with DNase 1 
and with almost complete disappearance of DNA bands at 60 min. This decrease in 
the circular and supercoiled band intensities was greatly reduced at higher N/P ratios 
of 6 and 12, suggesting that greater degree of DNA protection occurred with a higher 
concentration of polycarbonate 3d. We note that even though a supraphysiological 
dose of DNase 1 was used in this study (i.e. 50 U/ml vs. 0.17 ± 0.04 U/ml blood 
reported in healthy donors [162]), polycarbonate 3d could still afford a perceptible 






Figure 3.4. Nuclease degradation assay with polycarbonate 3d/DNA complexes at the 
indicated N/P ratios incubated with DNase 1 for 10, 30 and 60 min. Naked DNA 
treated with DNase 1 for 10 min was used as positive control. 
 
3.3.6. In vitro Luciferase Gene Expression in Various Cell lines 
To assess the suitability of using the polycarbonate 3d as a gene delivery vector, 
we performed the in vitro luciferase assay in HepG2, HEK293, MCF-7 and 4T1. As 
shown in Figure 3.5, the polycarbonate mediated high luciferase gene expression in 
all four cell lines in the presence of 10 % fetal bovine serum and in a cell type- and 
N/P ratio-dependent manner. The evaluation of gene transfection in the presence of 
serum offers a more accurate assessment of the gene delivery efficiency of 
polycarbonate 3d in serum protein-containing environments. The luciferase 
expression profile in HepG2 and HEK293 was similar, with luciferase activity 
increasing with N/P ratio to reach a plateau from N/P ratio 12 onwards (Figures 3.5A 
and 3.5B respectively). This result correlated well with the size and zeta potential data 
obtained earlier, which remained relatively constant from N/P ratio 12 onwards 
(Figure 3.2). The luciferase expression level induced by the polymer at the optimal 
N/P ratio in HepG2 cells was lower than that mediated by PEI, whereas it was at the 
same order of magnitude as that mediated by PEI in HEK293 cells. However, the 
Ladder DNA  DNase  0     10      30      60       0      10      30      60          0        10       30      60 min   
DNA   Naked DNA + 




polycarbonate induced higher luciferase expression (from N/P ratio 12) than that 
induced by PEI, in the mammary cancer MCF-7 (human) and 4T1 (mouse) cell lines 
tested (Figures 3.5C and 3.5D). For example, in 4T1, at N/P ratio 18, the normalized 
luciferase expression was determined to be 7.5 × 107, which is approximately 7 times 
higher than that achieved using PEI (1.1 × 107). 
 
 
Figure 3.5. In vitro luciferase expression level in (A) HepG2, (B) HEK293, (C) 
MCF-7 and (D) 4T1 cells, mediated by the polycarbonate at the various N/P ratios 
indicated. PEI/DNA complexes were prepared at N/P ratio 10. Results represent mean 
± standard deviation of 4 replicates. Polycarbonate concentrations in the order of N/P 
ratios specified: 0, 11.0, 22.0, 44.0, 66.1, 88.1 and 110.1 mg/L. 
 
3.3.7. Cytotoxicity of Polycarbonate 3d/DNA and PEI/DNA Complexes 
Overt cellular toxicity remains as one of the biggest challenges to overcome in the 
quest for a novel and efficient non-viral gene delivery vector [8, 12, 59, 115]. To 
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MTT assay in HepG2, HEK293, MCF-7 and 4T1 cell lines. As observed in Figure 3.6, 
cell viability was in excess of 90% for HepG2, HEK293 and 4T1 cell lines tested up 
to N/P ratio 18, whereas the same was achieved up to N/P ratio 12 for MCF-7. This 
degree of cell viability contrasts very favorably with that obtained with PEI, which 
induced significant cytotoxicities, yielding only 78% and 45% cell viability in HepG2 
and HEK293 cell lines respectively although it induced little cytotoxicity in MCF-7 
and 4T1 cell lines. Luciferase gene expression was observed to reach the highest level 
at N/P 18 in HepG2 and HEK293 cell lines. In the case of MCF-7 and 4T1, luciferase 
gene expression induced by polycarbonate at N/P 12 was already higher than that 


































































































Figure 3.6. Viability of (A) HepG2, (B) HEK293, (C) MCF-7 and (D) 4T1 cells after 
incubation with polycarbonate/DNA complexes at the various N/P ratios in 
comparison to PEI/DNA at N/P ratio 10. Results represent mean ± standard deviation 
of at least 8 replicates. Polycarbonate concentrations in the order of N/P ratios 
specified: 0, 11.0, 22.0, 44.0, 66.1, 88.1 and 110.1 mg/L. 
 
3.3.8. Particle Sizes and Zeta-potentials of Polycarbonate 3d/DNA and PEI/DNA    
Complexes Under Physiological Salt Conditions 
Under physiological conditions, the high concentration of counterions leads to 
rapid ionic exchanges and substitutions, which results in the weakening of 
electrostatic interactions between the polycation and polyanionic DNA [36]. In order 
to determine the sizes and zeta-potentials of the nanoparticles under high 
physiological salt conditions, we performed  measurements after 11× dilution of the 
pre-formed complexes with 1 × PBS (pH 7.2) to simulate physiological conditions as 
described previously [163, 164]. From Table 3.2, the sizes of the polycarbonate 
3d/DNA were found to increase drastically from less than 150 nm in a medium of low 
ionic strength (10 mM sodium phosphate buffer) (Figure 3.2) to more than 500 nm 
after 11× dilution with 1 × PBS. The particle size of PEI/DNA complexes formulated 
at N/P 10 was also found to have increased from 206 nm in HPLC water (Figure 3.2) 
to 294 nm after 11× dilution with PBS. The zeta-potentials of the polycarbonate 
3d/DNA and PEI/DNA complexes were found to be reduced compared to that shown 
in Figure 3.2 after dilution with PBS due to the charge neutralization effects of the 
high concentration of counterions present (Table 3.2). The large extent of size 
increment indicates that the nanoparticles formed lack colloidal stability under 
physiological salt conditions and further modifications to the cationic polycarbonate 





Table 3.2. Particle sizes and zeta-potentials of polycarbonate 3d/DNA and PEI/DNA 
complexes after 11 × dilution with 1 × PBS (pH 7.2) to simulate physiological 
conditions 
N/P ratio Size ± S.D. 
(nm) 
Zeta-potential 
± S.D. (mV) 
6 561.3 ± 31.9 0.3 ± 0.6 
12 562.5 ± 26.7 13.0 ± 0.7 
18 572.2  ± 26.0 15.0 ± 0.6 
24 573.8  ± 32.4 18.2 ± 0.9 
29 582.2  ± 16.9 16.1 ± 0.6 
PEI (N/P 10) 293.9  ± 3.9 16.0 ± 0.9 
 
3.4. Conclusions 
A novel platform for biodegradable synthetic gene vectors was developed using 
organocatalytic ROP of haloalkyl functionalized cyclic carbonates, followed by 
quaternization with bis-tertiary amine to yield cationic polycarbonates with well-
defined molecular weights and narrow polydispersities. The polycarbonate randomly 
incorporating ethyl side chains and positively charged side chains effectively 
condensed DNA to form positively charged nanoparticles. The polycarbonate/DNA 
nanocomplexes induced high luciferase expression efficiency in all four cell lines 
tested at relatively low N/P ratios in the presence of serum and yet induced minimal 
cytotoxicity at the optimal N/P ratios required for luciferase gene expression. 
Therefore, in this chapter, we established that the biodegradable cationic 
polycarbonate bearing quaternary and tertiary amines in the pendant chains has 
potential for use as safe and efficacious gene delivery vector in future therapeutic 
applications. The large size increment of the polycarbonate/DNA complexes under 
high salt conditions, however, suggests that further modifications to the cationic 
polycarbonate are required so as to enhance their colloidal stability. This important 





CHAPTER 4. Block Copolymers of Poly(ethylene glycol) and Cationic 
Polycarbonate: Effects of PEG Configuration on Gene Delivery 
 
4.1. Background 
In Chapter 3, we have described the design and synthesis of cationic 
polycarbonates bearing pendant functional amines via organocatalytic ROP and 
demonstrated that a polycarbonate randomly incorporating ethyl side chains and 
positively charged side chains induced high gene transfection efficiency with low 
cytotoxicities. However, we observed that the particle sizes of the 
polycarbonate/DNA complexes spontaneously increased to more than 550 nm after 
the addition of PBS (to simulate physiological salt conditions). This result is most 
probably a direct consequence of the charge screening effects induced by the high 
concentration of counterions present in PBS leading to a weakening of the 
electrostatic interactions between the cationic polycarbonate and DNA. The inherent 
colloidal instability of the system poses a significant problem for systemic 
applications and storage. As such, this Chapter is focused on the further development 
of well-defined cationic carbonate-based polymers with favorable properties for in 
vivo gene delivery applications. 
Polyethylene glycol (PEG) is a biocompatible and non-toxic motif most routinely 
utilized in the design of gene delivery vectors due to its well-documented ability to 
reduce toxicity, improve water-solubility, confer serum and colloidal stability, and 
prevent premature clearance of DNA complexes by cells of the reticuloendothelial 
system following systemic administration [86]. Recently, several studies have 
reported that different PEG molecular architectures (i.e. block or statistical form) 




efficiency of the DNA complexes to varying extents [88, 165]. Block copolymers, in 
particular, were identified to confer superior physicochemical properties to DNA 
complexes as well as result in higher gene transfection efficiencies.  
In our efforts to enhance the potential in vivo applicability of cationic 
polycarbonates, we built upon the above mentioned insights to design and synthesize 
well-defined block copolymers of PEG and cationic polycarbonate via metal-free 
organocatalytic living ROP of cyclic carbonate monomers containing alkyl bromide 
side chains using PEG-diol (Mn = 2.0 × 103 g·mol-1, PDI = 1.04) or monomethoxy 
PEG (Mn = 2.4 × 103 g·mol-1, PDI = 1.05) as the macroinitiator. A subsequent 
functionalization step with bis-tertiary amines provided quaternary and tertiary 
amines for DNA binding and endosomal buffering respectively. In this study, the 
most commonly encountered linear diblock (PEG-b-cationic polycarbonate) and 
triblock (cationic polycarbonate-b-PEG-b-cationic polycarbonate) configurations 
were employed to investigate the effects of PEG configuration on gene transfection. 
To this end, a non-PEGylated cationic polycarbonate was used as a control. Various 
aspects crucial to the success of gene delivery, including physicochemical (DNA 
binding, size, zeta-potential, and in vitro stability) and biological (cellular uptake and 
gene transfection) properties, were examined. In addition, biocompatibility testing for 
cytotoxicity and hemolytic potential was performed to evaluate the suitability of these 
cationic block copolymers for use in systemic gene delivery applications. 
 
4.2. Materials and Methods 
4.2.1. Materials 
Ultra pure (HPLC grade) water was obtained from J.T. Baker (U.S.A.). Phosphate-




BASE (Singapore) and diluted to the intended concentrations before use. 1 kb DNA 
ladder was purchased from New England Biolabs, while ethidium bromide solution 
was obtained from Biorad Laboratories (U.S.A.). Reporter lysis buffer and luciferin 
substrate were purchased from Promega (U.S.A.), and bicinchoninic acid (BCA) 
protein assay reagent was purchased from Pierce (U.S.A.). Plasmid DNA encoding 
the 6.4 kb firefly luciferase gene driven by the cytomegalovirus (CMV) promoter was 
obtained from Carl Wheeler, Vical (U.S.A.), amplified in Escherichia coli DH5α and 
purified using Endofree Giga plasmid purification kit from Qiagen. Ultrapure agarose, 
minimum essential medium (MEM), fetal bovine serum (FBS), sodium pyruvate, non-
essential amino acids, penicillin and streptomycin were all purchased from Invitrogen 
(U.S.A.). HepG2 cell line was purchased from ATCC (U.S.A.) and cultivated under 
the recommended conditions. 
 
4.2.2. Synthesis and Characterization of PEGylated and non-PEGylated Control 
Cationic Polycarbonates 
PEGylated block copolymers and control cationic polycarbonate (without PEG) 
were synthesized by Dr Yang Chuan (Institute of Bioengineering and Nanotechnology, 
A*STAR) through metal-free organocatalytic ring-opening polymerization (ROP) of 
cyclic carbonate MTC-PrBr using either PEG-diol, MPEG or 2,2-
bis(hydroxymethyl)propionic acid (bis-MPA) as the initiator, in the presence of 
thiourea (TU) and tertiary amine (DBU) catalysts allowing for the subsequent 
functional activation as previously reported [152]. Detailed synthetic procedures and 
molecular characterization information are available under Appendix B. 
 




Polycarbonate/DNA complexes were prepared as previously described under 
Section 3.2.3. 
 
4.2.4. Gel retardation assay 
DNA binding ability of the cationic polycarbonates was investigated using agarose 
gel electrophoresis as detailed in Section 3.2.4. 
 
4.2.5. Size and Zeta-potential Measurements 
The particle sizes and zeta potentials of the pre-formed polycarbonate/DNA 
complexes in 10 mM sodium phosphate buffer (pH 6.0) with and without salt 
adjustment via 11 × dilution with PBS, pH 7.2, were measured using the Zetasizer 
Nano (Malvern Instrument Ltd., Worcestershire, UK) equipped with a He-Ne laser. 
Scattered light was detected at an angle of 173˚ and at a set temperature of 25 °C. 
Particle size and zeta potential measurements were repeated for 3 runs per sample and 
reported as the mean ± standard deviation of 3 readings. 
 
4.2.6. Cellular Uptake Experiments 
Plasmid DNA (pCMV-luciferase) was labeled with YOYO-1 iodide (Molecular 
Probes, Invitrogen) by adding DNA to the intercalating nucleic acid stain at DNA 
base pairs to dye molar ratio of 300:1, followed by incubation for 2.5 h at room 
temperature in the dark. Fluorescently labeled DNA was stored at -20 °C until use. 
HepG2 cells (cell culture information is provided in Section 3.2.9) were seeded into 
12-well plates at a density of 3.0 × 105 cells per well. After 24 h, the culture media 
were replaced with 1 ml of fresh growth media, and 100 μL of polymer/DNA 




was added to each well. Following 4 h incubation at 37 °C, the polymer/DNA 
complexes were completely aspirated. The cells in each well were rinsed once with 1 
ml of PBS and 300 μL of trypsin was added. After a further 3 min of incubation at 
37 °C, 900 μL of media were added, and the cell suspension from each well was 
centrifuged at 1400 rpm for 5 min, after which the supernatant was discarded. The 
cells were rinsed once with 1 ml of ice-cold PBS and re-suspended in 500 μL of PBS. 
The percentage of cells which have taken up the DNA or polymer/DNA complexes 
and the geometric mean fluorescent intensities of the cells were analyzed by flow 
cytometry (BD LSR II) from 10000 events and reported as mean ± standard deviation 
from 2 independent experiments performed in triplicates. 
 
4.2.7. In vitro Luciferase Gene Expression Assay 
The in vitro gene transfection efficiency of the cationic polycarbonate/DNA 
complexes was investigated using the luciferase reporter gene in HepG2 cell line. 
Detailed experimental procedures are as described in Section 3.2.8. Data are 
expressed as mean ± standard deviations of four replicates from two independent 
experiments. 
 
4.2.8. MTT assay 
The cytotoxicity of the polycarbonate/DNA complexes was studied using the 
standard MTT assay protocol detailed in Section 3.2.9. Data are expressed as mean ± 
standard deviations from two independent experiments performed in eight replicates 
per N/P ratio. 
 




Fresh rat red blood cells were washed thrice in PBS and diluted to obtain a 4 % v/v 
suspension for use in this experiment. A 600 μL aliquot (comprising of 300 μL PBS 
and 300 μL red blood cells suspension) was added to each tube containing 60 μL of 
sodium phosphate buffer (pH 6.0) or polycarbonate/DNA complexes pre-formed at 
various N/P ratios. The tubes were then incubated at 37 °C for 1 h before they were 
centrifuged at 1000 × g for 5 min. Aliquots (100 μL) of supernatant were transferred 
to each well of a 96-well plate and analyzed for hemoglobin release at 576 nm using a 
microplate reader (TECAN). Red blood cells suspension containing sodium phosphate 
buffer was used as negative control. Absorbance of red blood cells lyzed with 0.1 % 
v/v Triton X-100 was taken as 100 % hemolysis. Percentage of hemolysis was 
calculated using the following formula:  
% Hemolysis = [(O.D.576nm of polycarbonate/DNA complexes − O.D.576nm of sodium 
phosphate buffer)/(O.D.576nm of 0.1% v/v Triton X-100 − O.D.576nm of sodium 
phosphate buffer)] × 100. 
 
4.2.10. Polymer Degradation Assay 
1 mg/ml of polycarbonate in PBS (pH 7.4) was incubated with or without lipase 
immobilized on acrylic resin at 37 °C with gentle shaking at 300 rpm (Eppendorf 
thermomixer comfort) for specific periods of time. At each time point, an aliquot of 
polycarbonate solution was sampled to prepare polycarbonate/DNA complexes (N/P 
ratios 1-5) and electrophoresed on 0.7% agarose gel in 0.5× TBE buffer at 80V for 55 
min. Changes in the DNA binding ability of the polycarbonate was visualized under 





4.2.11. Statistical Analysis 
Results were analyzed using the two-tailed Student’s t-test to determine statistical 
significance (Microsoft Excel). The difference between mean readings was considered 
to be statistically significant when p < 0.05. 
 
4.3. Results and Discussion 
4.3.1. Polymer Synthesis and Characterization 
The synthesis of the PEGylated block copolymers and control polycarbonate 
(without PEG) is summarized in Scheme 4.1a. After polymerization, acetic anhydride 
was added to cap both hydroxyl ends of the polymers. The polymers were isolated 
and purified before they were aminated using TMEDA in DMSO. To ensure that there 
was no intra- or intermolecular crosslinking, a large excess amount of TMEDA was 
used in the protonation reaction. The excess TMEDA was removed after precipitated 
twice in THF to give the final cationic triblock copolymer P(MTC-PrBr)-b-PEG-b-
P(MTC-PrBr) and diblock copolymer PEG-b-P(MTC-PrBr). Similarly, aminated bis-
MPA-(MTC-PrBr) was also obtained as control polycarbonate (without PEG).  
From the GPC chromatogram (Scheme 4.1b), the elution curves of both tri- and 
diblock copolymers showed a single unimodal peak with narrow polydispersity 
indices of 1.25 and 1.22, respectively. Scheme 4.1c shows the 1H NMR spectra of 
triblock copolymer P(MTC-PrBr)-b-PEG-b-P(MTC-PrBr) and its aminated derivative. 
All peaks attributed to PEG, MTC-PrBr, TMEDA and acetyl end groups were clearly 
observed in both proton spectra. Quantitative comparisons between the integral 
intensities of the peak of ethylene groups of PEG and methylene groups of MTC-PrBr 




the tri- and di- block copolymers, respectively as shown in Scheme 4.1a. However, 
not all the MTC-PrBr units of the two block copolymers were quaternized due to the 
reaction equilibrium and increased steric hindrance of the side chain at the late stage 
of the amination reaction [152]. Based on the NMR spectra of P(MTC-PrBr)-b-PEG-
b-P(MTC-PrBr), PEG-b-P(MTC-PrBr), and their aminated derivatives, 35 and 31 
MTC-PrBr units were aminated in the cationic triblock and diblock copolymers, 
respectively. Similarly, the control polycarbonate (without PEG) had narrow 
molecular weight distribution with polydispersity index of 1.24 before protonation. 
The protonated control polycarbonate had a comparable aminated block length with 


































































































































i. R =  H;    m = 45
ii. R = CH3; m = 55
i. 2n = 161; x = 2
ii. n =   82; x = 1
(a)
i. 2n’ = 35; x = 2
ii. n’ = 31; x = 1
iii. 2n’ = 41











Scheme 4.1. PEG-Polycarbonate block copolymers. (a) Synthesis procedures and 
structures of PEG-b-polycarbonates: (i) triblock copolymer P(MTC-PrBr)-b-PEG-b-
P(MTC-PrBr), (ii) diblock copolymer PEG-b-P(MTC-PrBr), and (iii) control 
polycarbonate (without PEG); (b) GPC diagram of block copolymer (i) and (ii), and 
the following molecular weight data were obtained : (i) Mn = 11,710, Mw/Mn = 1.25, 
and (ii) Mn = 5,740, Mw/Mn = 1.22; (c) 1H NMR of triblock copolymer in CDCl3, and 
its cationic derivative in DMSO-d6. 
 
4.3.2. DNA Binding Ability 
The DNA binding ability of the cationic polycarbonates was studied using agarose 
gel electrophoresis. It is demonstrated from Figure 4.1 that the triblock, diblock and 
control cationic polycarbonates effectively bound to DNA, giving rise to complete 
DNA retardation at low N/P ratios of 1, 3 and 3, respectively. This result indicates 
that the incorporation of PEG did not adversely interfere with DNA binding. 
Additionally, the lower N/P ratio required for complete DNA retardation suggests that 
the triblock copolymer exhibited better DNA binding ability compared to the other 
polymers. 
   
 
Figure 4.1. Electrophoretic mobility of plasmid DNA in polycarbonate/DNA 
complexes formed at the N/P ratios indicated. L represents 1 kb DNA ladder. 
 
4.3.3. Size and Zeta-potential Analyses 
Size and zeta-potential analyses further demonstrated that the cationic 
polycarbonates efficiently condensed DNA to form positively charged nanoparticles 
N/P ratio 
L   0   1    2   3    4   5  10 15      
Triblock 
copolymer 









(100–256 nm in diameter; 25–34 mV zeta-potential) with relatively low PDIs (0.1-0.3) 
in phosphate buffer (pH 6.0) (Figure 4.2). The PEG architectures of the 
polycarbonates were observed to influence the size and zeta-potential of the resultant 
DNA complexes to different extents despite their similar N contents and molecular 
weights. Notably, polyplexes formed with the triblock copolymer were found to be 
smaller (100–110 nm vs. 126–256 nm) and to possess higher zeta-potentials (30–32 
mV vs. 25–27 mV) than the corresponding diblock copolymer over the optimal ranges 
of N/P ratios determined to elicit biological effects (to be discussed in the next section) 
(Figure 4.2). The control polymer, on the other hand, formed similarly sized DNA 
complexes with marginally higher zeta-potentials as the triblock copolymer across the 
same range of N/P ratios tested (Figure 4.2).  
Although the exact mechanism for the above phenomenon is unclear at the 
moment, we hypothesize that diblock copolymer permits PEG chain extension into 
the aqueous milieu to form a thick hydrated shell while DNA condensation was 
mediated by the cationic end (Scheme 4.2a). This consequently resulted in polyplexes 
with larger hydrodynamic diameters and lower zeta-potentials due to the charge 
shielding effects of PEG. Recently, Dong et al. proposed a similar mechanism of 
DNA complex formation with diblock PEG-b-poly(carbonates-g-oligoethylenimine)s 
[110]. The DNA complexes were found to have significantly lower zeta-potentials 
than that formed with branched 25 kDa PEI. The possible polymer/DNA binding 
modes for the triblock copolymer were derived based on evidence from the literature. 
Firstly, several groups proposed that triblock copolymers comprising of a PEG block 
in the middle were likely to bend such that they formed a ‘flower-type’ structure, in 
which the PEG chains formed loops around the nanoparticle [166-168]. Through 1H 




D2O, Hua et al. showed the presence of two apparent signals which were respectively 
assigned to -CH2- in the PEG units and the solvent peak, whereas the signals of the 
protons in the poly(L-leucine) segment were found to have almost disappeared, 
suggesting that a hydrophobic poly(L-leucine) core and hydrophilic PEG shell 
structure was formed [168]. We speculate that the higher polyplex zeta-potentials 
observed with the triblock copolymer could be due to the above mode of interaction, 
with binding of DNA by both cationic polycarbonate blocks in the core and the 
middle hydrophilic PEG blocks bent and looped around the core, and at the same time, 
a small fraction of the triblock copolymer bound to DNA at one end, leaving PEG-
cationic polycarbonate chains exposed on the outside (Scheme 4.2b). This model was 
previously proposed in a study by Zhong et al., in which polyplexes formed with PEI-
b-PEG-b-PEI triblock copolymers displayed zeta-potentials lower than that of PEI 
homopolymers, but higher than the near neutral surface charge commonly described 
for PEGylated PEIs that induced low transfection efficiencies [169]. With a higher 
surface charge, greater electrostatic repulsion between the particles is expected to 




























































• Positive surface charges, enhanced 
electrostatic repulsion 
• ↑ Colloidal stability (less aggregation)
• ↑ Cellular uptake
• ↑ Gene expression  
Scheme 4.2. Proposed mechanism of DNA condensation by (a) diblock PEG-b-
cationic polycarbonate  and (b) triblock cationic polycarbonate-b-PEG-b-cationic 
polycarbonate. 
 
4.3.4. Stability Under Physiological Salt Conditions 
Under physiological conditions, the high salt concentration (150 mM NaCl) 
frequently leads to immediate and significant aggregation of polyelectrolyte 
complexes through charge screening effects [170, 171]. In this regard, a number of 
PEGylated gene delivery polymers have been observed to enhance DNA complex 
stability under high physiological salt concentrations [170, 172, 173]. Therefore, in 
order to evaluate and compare the salt stability of the polycarbonate/DNA complexes, 
we performed size and zeta-potential measurements after adjusting the ionic strength 
of the pre-formed complexes to approximate physiological conditions via 11 × 




formed with the triblock copolymer (N/P ratios 8-18) remained less than 145 nm, 
while that formed with the diblock and control polymers increased to 414–723 nm 
after adjustment of the ionic concentration (Figure 4.2). This outcome was found to be 
less dependent on the dilution or pH effects (Figure 4.3), and could be mainly 
attributed to the high salt concentration in the medium (Figure 4.2). The zeta-
potentials of the polyplexes were observed to decrease considerably presumably due 
to the increase in pH and the neutralization of surface charges by the high 
concentration of counterions present in PBS. Interestingly, the triblock 
copolymer/DNA complexes were found to possess higher zeta-potentials (15–18 mV) 
than the diblock (6–9 mV) and control (8–13 mV) polymer/DNA complexes. Taken 
together, these results suggest that the triblock copolymer afforded better salt stability 




                  
Figure 4.2. Size and zeta-potential analyses of polycarbonate/DNA complexes in low 
(10 mM sodium phosphate buffer) and high physiological salt conditions (via 11 × 
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polycarbonate-b-PEG-b-cationic polycarbonate/DNA complexes; (b) Diblock PEG-b-
cationic polycarbonate/DNA complexes (c) Non-PEGylated cationic polycarbonate 
control/DNA complexes.  
 
            
Figure 4.3. Effect of dilution and pH on size and zeta-potential of the DNA 
complexes. (a) Triblock cationic polycarbonate-b-PEG-b-cationic 
polycarbonate/DNA complexes; (b) Non-PEGylated cationic polycarbonate 
control/DNA complexes. Legend:  size in 10 mM sodium phosphate buffer, pH 6.0; 
 size after 11 × dilution of pre-formed complexes with HPLC water;  size after 11 
× dilution of pre-formed complexes with 10 mM sodium phosphate buffer, pH 7.2; 
 zeta-potential in 10 mM sodium phosphate buffer, pH 6.0;  zeta-potential 
after 11 × dilution of pre-formed complexes with HPLC water;  zeta-potential 








































































4.3.5. Comparison of Cellular Uptake of Polycarbonate/DNA Complexes 
The cellular uptake of the polycarbonate/DNA complexes was investigated via 
flow cytometry using YOYO-1 iodide labeled luciferase plasmid in HepG2 cells. The 
uptake of the complexes, which was expressed as (i) percentage of viable cells 
showing cellular fluorescence, and (ii) mean cellular level of fluorescence per cell, 
was shown to be dependent on the PEG architecture and N/P ratio (Figure 4.4).  
 
Figure 4.4. Effects of PEGylated cationic polycarbonate architecture [Triblock 
cationic polycarbonate-b-PEG-b-cationic polycarbonate/DNA complexes ( ); 
Diblock PEG-b-cationic polycarbonate/DNA complexes ( ); Non-PEGylated cationic 
polycarbonate/DNA complexes ( )] on (a) % cellular uptake and (b) geometric mean 
fluorescent intensity per cell. Results represent mean ± standard deviation of at least 
3-4 replicates from 2 independent experiments. * p < 0.01 relative to diblock and 
control polymers at the indicated N/P ratios. ** p < 0.01 relative to diblock copolymer 
at the indicated N/P ratios.  
 
In general, the triblock and control polymers demonstrated higher percentage of 
cellular uptake at N/P ratios 10 and 15, while the diblock copolymer exhibited similar 
levels of cellular uptake only at a higher N/P ratio of 200. At N/P ratio 15, a 
significantly higher percentage of triblock copolymer/DNA complexes (87 ± 6 %) 



















































and control polymer/DNA, respectively (p < 0.01) (Figure 4.4a). Additionally, at N/P 
10 and 15, the triblock copolymer/DNA complexes induced the highest geometric 
mean fluorescent intensity per cell, followed by that of the control, and lastly, the 
diblock copolymer (p < 0.01) (Figure 4.4b). The greater extent and degree of cellular 
uptake was in close agreement with the smaller sizes and higher zeta potentials 
obtained with the triblock copolymer/DNA complexes under physiological salt 
conditions (Figure 4.2a), which is similar to the pH and ionic concentration of the cell 
culture media. Polyplexes with smaller sizes (< 150 nm) and high zeta potentials are 
generally known to be more favorable for interaction with the negatively charged 
phospholipid cell membrane to mediate higher cellular uptake via endocytosis [115].  
The diblock copolymer/DNA complexes did not induce significantly different 
levels of mean cellular fluorescent intensity when compared to naked DNA (or N/P 0) 
treatment at low N/P ratios of 10 and 15 (p > 0.05). This observation may be 
attributed to the very low zeta-potentials of the DNA complexes at lower N/P ratios 
(e.g. - 17 mV at N/P 10) (Table 4.1). At a high N/P ratio of 200, however, diblock 
copolymer/DNA complexes with a positive zeta-potential of 9.3 mV induced 
fluorescent intensity levels comparable to the triblock copolymer at N/P 15 (p > 0.05) 










Table 4.1. Zeta-potential of diblock PEG-b-cationic polycarbonate/DNA complexes 
at lower N/P ratios.  
N/P ratio 
Zeta-potential ± S.D.  
¾¾¾¾¾ 
mV 
10 -16.6 ± 0.6 
20 -9.5 ± 0.2 
30 -8.3 ± 0.1 
 
a) DNA complexes were first formed in 10 mM sodium phosphate buffer (pH 6.0), 
followed by adjustment of the salt concentration and pH with 1 × PBS (pH 7.2) to 
approximate physiological conditions before measurement. 
 
4.3.6. Comparison of Luciferase Gene Expression in HepG2 Cell Line 
We subsequently evaluated the gene expression efficiency of the cationic 
polycarbonates/DNA complexes in HepG2 cells using the luciferase reporter gene. 
Consistent with the cellular uptake data observed earlier, triblock copolymer/DNA 
complexes induced higher luciferase expression than the diblock or control 
polymer/DNA complexes in the HepG2 cell line (Figure 4.5). For instance, the 
highest luciferase expression induced by triblock copolymer/DNA complexes (N/P 15 
and 18) was 1.9 × 108 RLU·mg protein-1 as compared to 3.6 × 107 and 1.7 × 106 
RLU·mg protein-1 of diblock copolymer (N/P 100) and control polymer (N/P 18), 
respectively. The luciferase expression levels mediated by the diblock 
copolymer/DNA complexes at low N/P ratios of 10 and 15 were again similar to 
transfection with naked DNA, and reached high levels only at elevated N/P ratios of ≥ 
100. It is thus evident that the luciferase expression levels corroborated well with the 
cellular uptake data observed earlier, clearly demonstrating that the PEG 




More importantly, the luciferase expression induced by triblock copolymer/DNA 
complexes was in the same order of magnitude as that of the PEI control in HepG2 
cells, i.e. 1.9 × 108 RLU·mg protein-1 at N/P 15 and 18 vs. 8.2 × 108 RLU·mg protein-1 
of PEI/DNA at N/P 10. The results obtained suggest that the triblock copolymer, with 
higher gene transfection efficiencies at lower N/P ratios (and hence, polymer 
concentration) than the diblock version, may be a more useful architecture for future 
cationic polycarbonate designs in gene delivery applications. 
     
Figure 4.5. Luciferase expression level of triblock cationic polycarbonate-b-PEG-b-
cationic polycarbonate/DNA complexes ( ), diblock PEG-b-cationic 
polycarbonate/DNA complexes ( ) and non-PEGylated cationic polycarbonate/DNA 
complexes ( ) in HepG2 cells. PEI/DNA complexes were prepared at N/P ratio 10 in 
HPLC grade water. 
 
4.3.7. Cytotoxicity of Polycarbonate/DNA Complexes 
An important pre-requisite for the successful application of non-viral gene delivery 
vectors is good biocompatibility [51]. In the systemic application of cationic 
polymer/DNA complexes, cytotoxicity is an influential and common factor restricting 















































































membrane disruptions precipitated by the high positive surface charges of the DNA 
complexes. As seen from Figure 4.6, the cell viabilities of the HepG2 cells remained 
≥ 85 % for most N/P ratios after treatment with DNA complexes formed from the 
various polycarbonates. As confirmed by the results of the MTT assay, the observed 
differences in the luciferase expression level among the three gene carriers were not 
due to varying levels of cytotoxicity induced by the individual complexes.  
                
Figure 4.6. Effect of cationic polycarbonate/DNA complexes on cytotoxicity in 
HepG2 cells. Polycarbonate concentration at specific N/P ratios 5, 8, 10, 12, 15, 18 
and 25 are: 19.3, 30.9, 38.6, 46.3, 57.9, 69.5 and 96.5 mg·L-1 for triblock cationic 
polycarbonate-b-PEG-b-cationic polycarbonate, and 17.1, 27.4, 34.2, 41.0, 51.3, 61.5 
and 85.5 mg·L-1 for non-PEGylated cationic polycarbonate control. N/P ratios 50, 100, 
140, 180 and 200 corresponds to 197.6, 395.3, 553.4, 711.5 and 790.6 mg·L-1 for 
diblock PEG-b-cationic polycarbonate. 
 
4.3.8. Hemolytic Potentials of Polycarbonate/DNA Complexes 
One of the major drawbacks of cationic gene delivery systems lies in a high 
propensity for red blood cells membrane disruption and lysis due to their highly 
positive charge density. As such, we next evaluated the blood compatibility of the 
polycarbonates and their resultant complexes. It is evident from Figure 4.7 that the 























at the optimal gene transfection N/P ratios for each polymer in rat red blood cells, 
implying that the complexes were highly amendable to systemic administration. 
        
Figure 4.7. Evaluation of hemolytic potential of cationic polycarbonates in rat red 
blood cells. 
 
4.3.9. Hydrolytic and Enzymatic Degradation Profiles of Triblock Copolymer 
The degradation of the polycarbonate backbone was performed by incubating 1 
mg/ml of triblock copolymer with or without 1 mg of lipase-immobilized beads in 
PBS (pH 7.4) at 37 °C with gentle shaking. At specified intervals, an aliquot of 
polymer solution was used to complex with DNA as described previously. As seen 
from Figure 4.8, the hydrolytic and enzymatic degradation of the triblock copolymer 
can be indirectly inferred from its gradual loss of DNA binding ability with time. At 0 
h, complete DNA retardation was attained at N/P 2, at 26 h, however, slight DNA 
retardation was observed at N/P 2, with a significant portion of DNA remaining 
uncomplexed even up to N/P 5. This result suggests that partial degradation of the 
polymer has plausibly occurred within the polycarbonate backbone, leading to the 
formation of shorter polymer chains with correspondingly reduced cationic charge 
















Triblock copolymer Triblock copolymer/DNA
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condensation was mediated by the polymer as evidenced by the more prominent upper 
and lower mobility bands of uncomplexed DNA compared to the image obtained at 
26 h. It is interesting to note that at both two time points (26 and 46 h), aliquots of the 
polymer solutions that have been incubated with lipase-immobilized beads exhibited a 
greater reduction in DNA binding ability compared to polymer solutions incubated in 
the absence of lipase (Figure 4.8). This result signifies that in addition to degradation 
by hydrolysis, the triblock copolymer was also susceptible to the enzymatic activity of 
lipase - a subclass of esterases which catalyze the hydrolysis of ester linkages. Our 
observation is consistent with reports in the literature on the susceptibility of aliphatic 
polycarbonates to degradation by hydrolysis [76, 79] and enzymatic activity of lipases 
[77, 174, 175] to yield alcohols and carbon dioxide. The rapid degradation of the free 
triblock copolymer chains is expected to be advantageous in vivo as it facilitates the 
clearance of the polymers after release of the DNA cargo [59, 176]. This effectively 
reduces the progressive accumulation of polymer chains in the body especially after 
repeated administrations. The reduced charged density of the intermediate degradation 
products is also expected to cause less cytotoxicity and hemolysis.  
Despite the rapid degradation of the free polymer chains within 26 h, the DNA 
binding ability of the triblock copolymer within the polymer/DNA complexes 
appeared to be retained up to 72 h, suggesting that the polymer degradation was 
markedly reduced (Figure 4.9). The delayed degradation of cationic polymers 
sequestered within DNA complexes has also been reported by others [61, 63]. A 
possible explanation for this phenomenon is that the reduction in self-hydrolysis of 
the carbonate ester linkages due to the unavailability of amines, which are involved in 
electrostatic interactions with DNA. Additionally, the sequestration of polymer chains 




degradation. The stability of the electrostatic interactions between the polymer and 
DNA in the high physiological salt conditions provided by PBS (pH 7.4) is expected 
to be favorable for the prolonged circulation of the nanoparticles to accumulate at the 
desired target site for therapeutic action. The ability of the triblock copolymer/DNA 
complexes to induce high luciferase expression as demonstrated in Figure 4.5, 
suggests that DNA can eventually be released from the complexes upon cellular 
uptake.  
   
 
Figure 4.8. Hydrolytic and enzymatic degradation of triblock cationic polycarbonate-
b-PEG-b-cationic polycarbonate in PBS (pH 7.4) in the absence or presence of 1 
mg·ml-1 lipase with time. 
 
Ladder   N/P 0     1          2         3         4         5 
0 h 
No lipase                                                 With lipase 
N/P 0       1          2          3          4          5           1          2          3          4           5 
26 h 
No lipase                                               With lipase 






Figure 4.9. Stability of triblock copolymer/DNA complexes formed at N/P 15 in PBS 
(pH 7.4) with gentle shaking at 37 °C. L: 1 kb DNA ladder; Lanes 1, 2, and 3 
represent naked DNA, triblock copolymer/DNA complex, and triblock 




Among the various architectures of PEGylated cationic polycarbonates with 
similar N contents and molecular weights, the triblock cationic polycarbonate-b-PEG-
b-cationic polycarbonate most efficiently bound and condensed DNA to yield 
complexes with favorable physicochemical properties including particle size, zeta-
potential, and salt stability, eventually leading to significantly higher extent and 
degree of cellular uptake in HepG2 cells. This result consequently translated into high 
luciferase gene expression, which was in the same order of magnitude as the PEI 
control, in serum-containing conditions. Importantly, the various cationic 
polycarbonates were found to be biocompatible; inducing low levels of cytotoxicity 
and hemolysis of red blood cells at the N/P ratios optimal for gene transfection. In 
addition, it was demonstrated that the triblock copolymer was susceptible to both 
hydrolytic and enzymatic degradation. Taken together, these preliminary data suggest 
that PEG in the triblock configuration may be a useful design for PEGylated cationic 
polycarbonates in future in vivo gene delivery applications. 
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CHAPTER 5. Galactose-Functionalized Polycarbonate Block Copolymer for 
Targeted Gene Delivery to Hepatocytes 
 
5.1. Background 
In Chapters 3 and 4, we have clearly demonstrated that the complexes formed with 
the cationic polycarbonate gene delivery systems possess highly desirable 
physicochemical properties such as small particle sizes and positive surface charges. 
The defining size properties of the nanocomplexes are expected to be highly favorable 
for passive accumulation in the human liver due to certain innate anatomical and 
pathophysiological features. Firstly, the presence of 100-200 nm fenestrations along 
the sinusoidal endothelial wall permits the extravasation of appropriately sized 
nanoparticles (< 200 nm) into the liver [177]. In the case of hepatocellular carcinoma, 
passive accumulation of the nanoparticles less than 400-600 nm can also occur in the 
liver tumor via the enhanced permeation and retention (EPR) effect that was first 
described by Matsumura and Maeda in 1986 [178]. Despite the excellent ability of 
nanoparticles to passively target to the liver, the incorporation of a targeting ligand in 
the gene delivery system is expected to greatly enhance cellular uptake via receptor-
mediated endocytosis and to confer cell specificity, thereby minimizing any unwanted 
effects to other cell types.  
The asialoglycoprotein receptor (ASGP-R) is a hepatocyte-specific C-type lectin 
that displays high binding affinity to serum glycoproteins bearing terminal galactose 
and N-acetyl-galactosamine residues for their removal from the circulation [179]. This 
innate physiological mechanism was exploited by Wu and Wu, who demonstrated for 
the first time in 1987 that selective gene delivery to ASGP-R positive HepG2 can be 




[27]. It was further shown in their subsequent study that selective the conjugates 
effectively mediated selective accumulation and gene expression in the liver 
following intravenous administration in rats [28]. Clinically, ASGP-R expression has 
been found to be retained on hepatocellular carcinomas (HCCs), albeit at lower levels 
compared to normal hepatocytes suggesting that cellular targeting approaches to 
ASGP-Rs may be less efficient for HCC cells [180, 181]. Nonetheless, several groups 
have demonstrated high levels of biodistribution and better gene expression in 
subcutaneous HCC tumors due to the combined EPR effect and active ASGP-R 
targeting mechanism compared to the normal liver [182, 183]. Based on these 
evidences, the incorporation of ASGP-R ligands in gene delivery systems is expected 
to be useful for the delivery of therapeutic genes to afflicted hepatocytes in HCC or 
hepatitis viral treatments, particularly in the current absence of satisfactory curative 
treatment options for these liver diseases.     
Due to the commercial availability of raw materials and ease of synthetic 
preparations, galactosylated poly-L-lysine [184] and PEI [93, 183, 185] are currently 
among the most frequently reported polymeric gene vectors used for hepatocyte 
targeting, however, their non-biodegradability and/or high polydispersities, are likely 
to restrict their in vivo applications. Additionally, the direct conjugation of lactobionic 
acid or lactose to the primary amines present in the cationic polymers has been 
associated with a decrease in charge densities for gene binding and the consequent 
reduction in gene transfection efficiencies [93]. Hence, the copolymerization of a 
polymer containing galactose side chains with a cationic polymer appears to be a 
more practical approach to incorporate cellular targeting functionalities, while 
ensuring that the DNA binding and gene transfection efficiency of the cationic 




In order to fully capitalize on passive and active targeting mechanisms for selective 
gene delivery to hepatocytes, we designed and synthesized well-defined 
biodegradable diblock galactose- or glucose-functionalized cationic polycarbonates 
(designated Gal-APC and Glu-APC, respectively) with narrow polydispersities via 
metal-free organocatalytic living ring-opening polymerization (ROP) of sugar-
functionalized cyclic carbonate monomers using 4-methylbenzyl alcohol (MBA) as 
the initiator, followed by the sequential polymerization of cyclic carbonate monomers 
containing alkyl bromide side chains. A subsequent quaternization reaction of the 
alkyl bromide with bis-tertiary amines provided quaternary and tertiary amines for 
DNA binding and endosomal buffering respectively. The aminated polycarbonate 
block is expected to undergo electrostatic interactions with DNA to form positively 
charged nanocomplexes exposing galactose residues on the surface which may lead to 
the passive accumulation, binding and internalization of the complexes via the ASGP-
Rs present on the hepatocyte cell surface (Scheme 5.1). In this Chapter, DNA binding 
ability and the physicochemical properties including particle size, zeta-potential and 
colloidal stability of the Gal-APC/DNA and Glu-APC/DNA complexes were 
evaluated. The gene transfection efficiency and cell selectivity of the Gal-APC/DNA 
complexes, in comparison with Glu-APC/DNA complexes, was investigated in 
ASGP-R positive human hepatocellular carcinoma, HepG2 and ASGP-R negative 
human cervical cancer, HeLa cell lines. Biocompatibility testing of the DNA 
complexes was performed in the HepG2 cell line. Lastly, the ligand-mediated cellular 
internalization of the Gal-APC/DNA complexes was confirmed using the asialofetuin 




                   
Scheme 5.1. Passive and active targeting strategies of galactose-functionalized 
cationic polycarbonate block copolymer/DNA complexes. (a) Formation of 
nanocomplexes with surface galactose moieties via electrostatic interactions; (b) 
Nano-sized property (< 200 nm) of complexes facilitates extravasation through larger 
fenestrations in the liver sinusoid endothelial cell wall to accumulate in the space of 
Disse; (c) Recognition and binding of galactose ligands by the asialoglycoprotein 
receptors (ASGP-R) present on the hepatocyte cell surface induce clathrin-mediated 
endocytic uptake of the nanoparticles. Image modified with permission from [91]. 
Copyright (2010) Elsevier.  
 
5.2. Materials and Methods 
5.2.1. Materials 
Ultra pure (HPLC grade) water was obtained from J.T. Baker (U.S.A.). Phosphate-
buffered saline (PBS) and tris-borate-EDTA (TBE) buffers were purchased from 1st 
BASE (Singapore) and diluted to the intended concentrations before use. 1 kb DNA 
ladder was purchased from New England Biolabs, while ethidium bromide solution 
was obtained from Biorad Laboratories (U.S.A.). Reporter lysis buffer and luciferin 
substrate were purchased from Promega (U.S.A.), and bicinchoninic acid (BCA) 







the 6.4 kb firefly luciferase gene driven by the cytomegalovirus (CMV) promoter was 
obtained from Carl Wheeler, Vical (U.S.A.), amplified in Escherichia coli DH5α and 
purified using Endofree Giga plasmid purification kit from Qiagen. Asialofetuin and 
25 kDa branched polyethylenimine were purchased from Sigma-Aldrich. Ultrapure 
agarose, minimum essential medium (MEM), fetal bovine serum (FBS), sodium 
pyruvate, non-essential amino acids, penicillin and streptomycin were all purchased 
from Invitrogen (U.S.A.). HepG2 and HeLa cell lines were purchased from ATCC 
(U.S.A.) and cultivated under the recommended conditions. 
 
5.2.2. Synthesis and Characterization of Sugar-functionalized Cationic 
Polycarbonate Block Copolymers 
Galactose- and glucose-functionalized polycarbonate block copolymers were 
synthesized by Dr Yang Chuan (Institute of Bioengineering and Nanotechnology, 
A*STAR) in a one-pot, two-step process. Metal-free organocatalytic ring-opening 
polymerization (ROP) of the sugar-functionalized cyclic carbonate monomers was 
first performed in the presence of thiourea (TU) and tertiary amine (DBU) catalysts, 
using 4-methylbenzyl alcohol (MBA) as the initiator. Upon near quantitative 
conversion, a second monomer 3-bromopropyl 5-methyl-2-oxo-1,3-dioxane-5-
carboxylate (MTC-PrBr) was added to the reaction mixture for the growth of the 
second block, allowing for the subsequent functional activation as previously reported 
[152]. Detailed synthetic procedures are available under Appendix C. 
 





Polycarbonate/DNA complexes were prepared as previously described under 
Section 3.2.3. 
 
5.2.4. Gel retardation assay 
DNA binding ability of the cationic polycarbonates was investigated using agarose 
gel electrophoresis as detailed in Section 3.2.4. 
 
5.2.5. Size and Zeta-potential Measurements 
The particle sizes and zeta potentials of the pre-formed polycarbonate/DNA 
complexes in 10 mM sodium phosphate buffer (pH 6.0) with and without salt 
adjustment via 11 × dilution with PBS, pH 7.4, were measured using the Zetasizer 
Nano (Malvern Instrument Ltd., Worcestershire, UK) equipped with a He-Ne laser. 
Scattered light was detected at an angle of 173˚ and at a set temperature of 25 °C. 
Particle size and zeta potential measurements were repeated for 3 runs per sample and 
reported as the mean ± standard deviation of 3 readings. 
 
5.2.6. Cell Culture and MTT Assay 
Human hepatocellular carcinoma cell line, HepG2, was maintained in MEM 
growth medium, while human cervical cancer cell line, HeLa, was cultured in RPMI-
1640. All growth media used were supplemented with 10% FBS, 1 mM sodium 
pyruvate, 100 U/mL penicillin and 100 mg/mL streptomycin and cultured at 37oC, 
under an atmosphere of 5% CO2 and 95% humidified air. 
 The cytotoxicity of the polycarbonate/DNA complexes was studied using the 




standard deviations from two independent experiments performed in eight replicates 
per N/P ratio. 
 
5.2.7. In vitro Luciferase Gene Expression Assay 
The in vitro gene transfection efficiencies of the galactose- and glucose-
functionalized polycarbonate block copolymer/DNA complexes were investigated 
using the luciferase reporter gene in HepG2 and HeLa cell lines. HepG2 and HeLa 
were seeded onto 24-well plates at a density of 8 × 104 and 1.2 × 105 cells per well, 
respectively. Detailed experimental procedures are provided in Section 3.2.8. Unless 
otherwise stated, 2 µg of pCMV-luc was used in the 50 µL of polycarbonate/DNA 
complexes added to each well. Data are expressed as mean ± standard deviations of at 
least two independent experiments performed in quadruplicates. 
 
5.2.8. Asialofetuin (ASF) Competition Assay 
HepG2 were seeded onto 24-well plates at a density of 8 × 104 cells per well. After 
24 h, the cells were pre-incubated with 0, 0.5, 1 and 2 mg/ml of ASF in 500 µL of 
fresh media per well for 1 h before 50 µL of galactose- and glucose-functionalized 
polycarbonate block copolymer/DNA complexes were added and allowed to transfect 
for 4 h. After the 4 h incubation, the transfection medium was replaced with fresh 
media and the luciferase expression levels were analyzed as described in Section 5.2.7 
after a further incubation of 68 h.  
 




Results were analyzed using the two-tailed Student’s t-test to determine statistical 
significance (Microsoft Excel). The difference between mean readings was considered 
to be statistically significant when p < 0.05. 
 
5.3. Results and discussion 
5.3.1. Polymer Synthesis and Characterization 
Saccharide-based polycarbonates containing galactose/glucose and alkyl bromide 
functional pendant groups were synthesized by ROP of the two monomers derived 
from 2,2-bis(methylol)propionic acid bearing pendant functional protected sugar 
groups (MTC-ipGal or MTC-ipGlu) and bromopropyl groups (MTC-PrBr) using 4-
methylbenzyl alcohol as the initiator, in the presence of DBU and TU catalysts 
(Scheme 5.2). The polymers with the protected galactose or glucose group were 
obtained in high yields and narrow molecular weight distribution (PDI is 1.19 and 
1.18, respectively). The compositions of the precursor block copolymers were 
estimated from 1H NMR spectroscopy and there were 22 MTC-ipGal and 48 MTC-
PrBr units in the galactose-based polymer and 27 MTC-ipGal and 61 MTC-PrBr units 
in the glucose-based polymer. After removing the protecting groups of sugars via 
acidic hydrolysis, the sugar-based polymers were protonated using TMEDA, giving 
















































































































Scheme 5.2. Synthesis procedures and structures of galactose- or glucose-
functionalized cationic polycarbonate block copolymers. 
 
5.3.2. DNA Binding Ability 
The DNA binding abilities of galactose- and glucose-functionalized cationic 
polycarbonates were first evaluated by agarose gel electrophoresis. From Figure 5.1, it 
is evident that Gal-APC and Glu-APC effectively bound to DNA, giving rise to 
complete DNA retardation at very low N/P ratios of 3 and 4, respectively. Similar to 
the result observed with the triblock and diblock PEGylated copolymers discussed in 




sugar moieties to the amine-functionalized polycarbonate did not appear to adversely 
interfere with DNA binding.  
         







Figure 5.1. Electrophoretic mobility of plasmid DNA in Gal-APC and Glu-
APC/DNA complexes formed at the N/P ratios indicated.  
 
5.3.3. Size and Zeta-potential Analyses 
The particle sizes of the Gal-APC/DNA and Glu-APC/DNA complexes were 
determined by dynamic light scattering. As shown in Table 5.1, Gal-APC and Glu-
APC effectively condensed DNA into nanoparticles that were ≤ 97.4 nm in diameter. 
The DNA complexes were found to be positively charged, with zeta-potentials in the 
range of 28 to 34 mV. The slightly higher zeta-potentials of the Glu-APC/DNA 
complexes compared to the Gal-APC/DNA complexes (i.e., 32-34 mV vs. 28-30 mV) 
may be attributed to the greater number of the amine-functionalized carbonate 
monomers in the former. Taken together, the small sizes (< 150 nm) and positive 
zeta-potentials of the resultant DNA complexes are expected to be favorable for 
promoting cellular uptake via endocytosis. 
 
Table 5.1. Size and zeta-potential of Gal-APC/DNA complexes and Glu-APC/DNA 





















20 94.0 ± 0.8 27.6 ± 1.2 96.6 ± 1.1 32.0 ± 1.0 
30 97.4 ± 1.4 28.8 ± 1.0 92.7 ± 0.4 32.0 ± 0.9 
40 96.7 ± 1.0 28.4 ± 1.5 94.6 ± 0.3 31.9 ± 1.8 
50 95.6 ± 0.6 29.6 ± 0.7 93.3 ± 1.0 33.6 ± 1.2 
60 96.3 ± 1.0 29.8 ± 0.8 95.2 ± 0.8 33.5 ± 1.2 
 
5.3.4. In vitro Salt Stability 
To evaluate the colloidal stability of the Gal-APC/DNA complexes under 
physiological salt conditions, we measured the hydrodynamic diameter of the DNA 
complexes after increasing the ionic strength of the medium via 11 × dilution with 1 × 
PBS (pH 7.4). From Figure 5.2a, it was demonstrated that the sizes of the polyplexes 
after dilution with 1 × PBS were increased to a larger extent at the lower N/P ratios of 
20 and 30, but increased only marginally to around 102-110 nm at N/P ratios of above 
40 as compared to that measured in the lower ionic strength of 10 mM sodium 
phosphate buffer (listed in Table 5.1). Despite the slight size increment, the 
hydrodynamic diameter of the polyplexes remained well below 200 nm, with a 
gradual decrease in size as a function of N/P ratio until about N/P 40 where the size 
stabilizes. As expected, the zeta-potentials of the Gal-APC/DNA complexes were 
found to be reduced from 28-30 mV (Table 5.1) to approximately 13 mV after the 
increase in the ionic strength of the medium. This decrease in zeta-potentials could be 




Additionally, the Gal-APC/DNA complexes formed had relatively homogenous size 
distributions (PDI ≤ 0.2) across all the N/P ratios tested (see representative size 
distribution chart in Figure 5.2b). The small sizes, positive zeta-potentials and narrow 
size distributions of the Gal-APC/DNA complexes that were retained under 
physiological salt conditions strongly suggest that the polyplexes may be effective at 
navigating physiological barriers to accumulate and mediate cellular uptake by 
hepatocytes in the human liver.                                                         
           
Figure 5.2. (a) Particle size and zeta-potential measurement of Gal-APC/DNA 
complexes under physiological salt condition (via 11 × dilution with PBS, pH 7.4) as 
a function of N/P ratios. (b) Size distribution of Gal-APC/DNA complexes prepared 






































The stability of the Gal-APC/DNA complexes under high salt conditions was also 
investigated by measuring the particles sizes at specific time intervals after 11 × 
dilution with PBS, pH 7.4. As expected, the sizes of the Gal-APC/DNA complexes 
were increased as a function of time in physiological salt conditions (Figure 5.3). This 
result is consistent with numerous reports in the literature in which positively charged 
particles show a tendency to aggregate with time [36]. This phenomenon has been 
attributed to the charge screening effects provided by the high concentration of 
counterions present in PBS, leading to gradual weakening of the electrostatic 
interactions between the cationic polymer and DNA and/or aggregation of polyplexes 
due to the reduction in surface charges. Fortunately, unlike the rapid and extremely 
large size increments observed with PEI/DNA complexes under physiological salt 
conditions (150 mM NaCl) [36], the sizes of the Gal-APC/DNA complexes increased 
rather slowly with time. Importantly, despite the size increments, the sizes of the Gal-
APC/DNA complexes formed at N/P ratios 40 and 60 remained relatively small (< 
218 nm) after 4 h and are still within the desirable range for gene delivery 
applications. The cationic polymer concentration (or N/P ratio) was also found to 
have a profound influence on the colloidal stability of the Gal-APC/DNA complexes 
with time (Figure 5.3). At the higher N/P ratio of 60, the Gal-APC/DNA complexes 
displayed a more gradual increase in size from 102 to 158 nm, while the 
corresponding complexes prepared at N/P 40 were found to increase to a greater 
extent from 105 to 218 nm within 4 h in PBS. The slower rate of size increment at the 
higher N/P ratio might be due to the greater excess of polymer chains in the solution, 
which could result in the neutralization of free charges, effectively preserving to a 
larger extent the degree of electrostatic interactions between the cationic 




                            
Figure 5.3. Time-dependent changes in particle sizes of the Gal-APC/DNA 
complexes formed at N/P ratios 40 and 60 after 11 × dilution with PBS, pH 7.4.   
     
5.3.5. Optimization of DNA Concentration for Gene Transfection 
To determine if the transfection efficiency of Gal-APC was affected by the amount 
of plasmid DNA used, we measured the luciferase expression levels after transfecting 
HepG2 cells with Gal-APC/DNA complexes containing 1.5, 2.0 and 2.5 µg of 
luciferase reporter gene (pLuc) per well at fixed N/P ratios of 40 and 60. As seen from 
Figure 5.4a, a reduction in the amount of pLuc from 2.5 µg, which is the usual 
amount used in the gene transfection experiments described in Chapters 3 and 4, to 
2.0 µg did not significantly decrease luciferase gene expression. A further reduction 
of pLuc to 1.5 µg led to a significant drop in luciferase gene expression which is 
highly undesirable for gene delivery applications. At a fixed N/P ratio, a reduction in 
the amount of DNA used, effectively leads to the need for less cationic polymer to 
mediate DNA complexation. This approach thus offers a useful strategy to overcome 
potential cytotoxicity issues associated with the use of higher amounts of the cationic 
polymer without having to compromise on gene expression levels. Indeed, the cell 
viabilities of the Gal-APC/DNA complexes comprising of 2.0 µg DNA were 


























(Figure 5.4b). Based on the above results, the lower amount of 2.0 µg pLuc was 
chosen for use in subsequent experiments. 
 
 
Figure 5.4. Optimization of plasmid DNA amount for luciferase expression. (a) 
Luciferase expression levels and (b) cell viabilities after HepG2 cells were transfected 
with the indicated amounts of plasmid DNA using Gal-APC at fixed N/P ratios. Cell 
viability results represent mean ± standard deviation of 2 independent experiments 
performed in 8 replicates.  
 
5.3.6. Cytotoxicity of Galactose- and Glucose-functionalized Polycarbonate Block 
Copolymers 
The cytotoxicity of the Gal-APC and Glu-APC/DNA complexes was investigated 
























































complexes formed with Gal-APC and Glu-APC demonstrated good toxicity profiles, 
with cell viabilities of greater than 90 % across the N/P ratios tested. Similar to the 
cell viability data shown in Chapters 3 and 4, this result demonstrates that 
functionalized polycarbonates are favorable for gene delivery applications.  




















Figure 5.5. Effect of Gal-APC and Glu-APC/DNA complexes on cell viability in 
HepG2. Polymer concentration in the order of N/P ratios specified are 35.9, 71.7, 
107.6, 143.5, 179.3, 215.2, and 251.1 mg·L-1 for Gal-APC, and 35.3, 70.5, 105.8, 
141.0, 176.3, 211.5, and 246.8 mg·L-1 for Glu-APC, respectively. Results represent 
mean ± standard deviation of 2 independent experiments performed in 8 replicates. 
 
5.3.7. Luciferase Gene Expression in ASGP-R Positive and ASGP-R Negative Cell 
Lines  
HepG2 is a well-characterized cell line that expresses an abundance of 
asialoglycoprotein receptors (ASGP-Rs) on its cell surface [179] and is therefore a 
commonly used model to investigate gene delivery systems designed for targeting to 
liver parenchymal cells [185-187].  As such, the gene transfection ability of Gal-APC 
and Glu-APC was first evaluated in HepG2 at various N/P ratios in serum-containing 
medium. Figure 5.6a shows that the luciferase expression levels induced by Gal-




expression from N/P ratio 20 until a peak is reached at N/P 50. The highest level of 
gene expression induced by the Gal-APC/DNA complexes at N/P 50 was 6.4 × 107 
RLU/mg protein, which was within one order of magnitude of the 5.1 × 108 RLU/mg 
protein obtained with the commercially available 25 kDa branched PEI benchmark. 
Importantly, the luciferase expression levels induced by the Gal-APC/DNA 
complexes in the ASGP-R positive HepG2 cell line were found to be consistently 
higher than that obtained with the Glu-APC/DNA complexes across all the N/P ratios 
tested (p < 0.01) (Figure 5.6a). At N/P ratio 50, for instance, the luciferase expression 
level mediated by Gal-APC/DNA complexes was approximately 4 times higher than 
that of the Glu-APC/DNA complexes. In stark contrast, there was no significant 
difference between the luciferase expression levels induced by Gal-APC/DNA and 
Glu-APC/DNA complexes in the ASGP-R negative HeLa cell line (p > 0.05) (Figure 
5.6b). The gene transfection results obtained clearly demonstrate good selectivity of 
the Gal-APC/DNA complexes for the ASGP-R positive HepG2 cell line, but not in 




                     
Figure 5.6. Luciferase expression induced by Gal-APC and Glu-APC/DNA 
complexes in (a) HepG2 and (b) HeLa cell lines. Results represent mean ± standard 
deviation of 4 replicates. PEI/DNA complexes were prepared at N/P ratio 10 in HPLC 
grade water. * p < 0.01 relative to the luciferase expression level induced by Glu-
APC/DNA complexes at the indicated N/P ratio. 
 
5.3.8. Asialofetuin Competition Assay 
To confirm that the enhanced luciferase gene expression induced by the Gal-
APC/DNA complexes was indeed mediated through the ASGP-R, HepG2 cells were 
co-incubated with different concentrations of asialofetuin (ASF), a natural ligand for 
the ASGP-R containing approximately 12.4 galactosyl residues per protein molecule 
during gene transfection [94, 188]. It is evident from Figure 5.7 that an increase in the 
















































































































































mediated by the Gal-APC/DNA complexes formed at N/P ratio 40 in HepG2 cells. A 
2, 3 and 6 times reduction in luciferase gene expression was obtained at ASF 
concentrations of 0.5, 1 and 2 mg/ml, respectively when compared to the level 
mediated by Gal-APC/DNA complexes in the absence of the competing ligand (p < 
0.05). Gene expression induced by the Glu-APC/DNA complexes, on the other hand, 
was not significantly affected by changes in ASF concentration. Additionally, the 
luciferase expression level produced by the Gal-APC/DNA complexes at the highest 
concentration of ASF tested (2 mg/ml ASF), was not significantly different from that 
of Glu-APC/DNA complexes at the same N/P ratio (0 mg/ml ASF). Therefore, these 
results strongly suggest that the higher luciferase gene expression induced by the Gal-
APC/DNA complexes can be attributed to the recognition and binding of the 
galactose residues on the surface of the complexes by the ASGP-Rs on the surface of 
the HepG2 cells, leading to enhanced cellular uptake through the clathrin-dependent 
receptor-mediated endocytotic pathway that has been described for the internalization 
of substrates via the ASGP-Rs [179]. 
   
Figure 5.7. Effect of asialofetuin on luciferase expression induced by Gal-APC/DNA 




























































concentration of asialofetuin for 1 h before Gal/DNA or Glu/DNA complexes were 
added and incubated further for 4 h. Gal-APC/DNA and Glu-APC/DNA complexes 
were prepared at N/P ratio of 40. Results represent mean ± standard deviation of 4 
replicates. * p < 0.05 relative to the luciferase expression level induced by Gal-
APC/DNA complexes in the absence of asialofetuin. 
 
5.4. Conclusions 
In this chapter, we have successfully designed and synthesized novel diblock 
sugar-functionalized cationic polycarbonate copolymers; and demonstrated for the 
first time that the galactose-functionalized cationic polycarbonate is a safe and 
efficient non-viral gene carrier for hepatocyte targeting. The sugar-functionalized 
cationic polycarbonate block copolymers demonstrated excellent physicochemical 
properties in terms of DNA binding and condensation to form positively charged 
nanoparticles that were less than 100 nm in diameter and with a zeta-potential of 
approximately 30 mV. Additionally, the galactose-functionalized cationic 
polycarbonate/DNA complexes formed were stable under high physiological salt 
conditions. The DNA complexes formed with the sugar-functionalized cationic 
polycarbonate block copolymers were found to induce minimal cytotoxicity in the 
human hepatocellular carcinoma cell line, HepG2. The galactose-functionalized 
cationic polycarbonate efficiently enhanced luciferase gene expression in the ASGP-R 
positive HepG2, but not in the ASGP-R negative HeLa cell line when compared with 
the glucose-functionalized cationic polycarbonate control. Competition study using 
asialofetuin, a natural ligand for ASGP-R revealed that the increased gene expression 
observed with the galactose-functionalized cationic polycarbonate in HepG2 was due 
to enhanced cellular uptake of the DNA complexes via ASGP-R mediated 




copolymer has great potential to selectively deliver therapeutic genes to hepatocytes, 
particularly in liver cancer or hepatitis viral infection treatments. 




CHAPTER 6. Conclusions and Future Perspectives 
 
The overall aim of this thesis was to design and evaluate a novel class of 
biodegradable cationic polycarbonates synthesized by metal-free living 
organocatalytic ring-opening polymerization (ROP) of functionalized cyclic carbonate 
monomers, followed by a protonation reaction with bis-tertiary amines to yield 
quaternary and tertiary amines for gene delivery applications. We tested the 
hypothesis that the well-defined cationic polycarbonates with predictable molecular 
weights and narrow polydispersities conferred by organocatalytic ROP are safe and 
effective synthetic non-viral gene carriers. In aim (1), we provided an important 
proof-of-concept that a rationally designed amine-functionalized polycarbonate can 
effectively condense DNA to form complexes with highly desirable physicochemical 
properties. It was demonstrated that the cationic polycarbonate/DNA complexes 
mediated luciferase gene expression that was comparable or superior to the 25 kDa 
branched PEI benchmark, while inducing minimal cytotoxicities at the optimal N/P 
ratios for gene transfection in a panel of mammalian cell lines. 
In aim (2), biodegradable block copolymers of PEG and amine-functionalized 
polycarbonate were designed to capitalize on the various favorable properties of PEG, 
such as hydrophilicity and serum and colloidal stability, so as to improve on the 
potential in vivo applicability of cationic polycarbonates. In Chapter 4, we 
investigated for the first time the effects of PEG configuration within cationic block 
copolymers on gene transfection. This was achieved by comparing the effects of a 
triblock cationic polycarbonate-b-PEG-b-cationic polycarbonate, diblock PEG-b-
cationic polycarbonate and non-PEGylated cationic polycarbonate control with 




was demonstrated that the PEG configuration within block copolymers indeed plays 
an important role in influencing gene delivery and that the triblock copolymer 
exhibited more favorable physicochemical properties (i.e., DNA binding, size, zeta-
potential, and in vitro stability) and biological effects (i.e., cellular uptake and 
luciferase reporter gene expression) in a HepG2 model. Similar to the results shown in 
Chapter 3, the various cationic polycarbonate/DNA complexes were consistently 
found to be biocompatible; inducing minimal cytotoxicities and hemolysis. 
In aim (3), a galactose-functionalized cationic polycarbonate block copolymer 
(Gal-APC) was designed for the first time to exploit the innate asialoglycoprotein 
receptor (ASGP-R)-mediated binding and internalization mechanism of serum 
glycoproteins bearing galactose residues for selective gene delivery to hepatocytes. It 
was shown that the Gal-APC formed DNA complexes with desirable physicochemical 
properties. A significantly higher luciferase expression was induced by the Gal-
APC/DNA complexes in the ASGP-R positive HepG2 than in the ASGP-R negative 
HeLa cell line, clearly demonstrating the hepatocyte selectivity of the Gal-APC/DNA 
system. The receptor-mediated uptake of the Gal-APC/DNA complexes was 
confirmed in a competition assay using asialofetuin, which is the natural ligand for the 
ASGP-R. 
This present work has raised several issues and identified potential opportunities 
that can be pursued in future investigations. Firstly, through our preliminary study 
performed in Chapter 4, we have ascertained that in addition to the PEG molecular 
architecture (i.e. block or statistical form) in cationic copolymer systems as previously 
described [88, 165], the PEG configuration within block copolymers also greatly 
influences the physicochemical and biological properties of their resultant DNA 




uptake and gene transfection patterns have been widely reported in the literature, we 
propose that further investigations in a wider range of human cell lines should be 
performed to determine if the triblock copolymer configuration is indeed a broadly 
applicable design to adopt in PEGylated cationic polycarbonate systems. As different 
molecular weights of PEG have been shown to greatly influence the stability and gene 
transfection efficiency of cationic polymer systems [87, 189], this aspect should also 
be taken into consideration in future studies so as to identify the most optimal system 
for future in vivo gene delivery applications. 
The Gal-APC system was designed to encompass both passive and active targeting 
strategies for in vivo gene delivery to hepatocytes. In Chapter 5, we have successfully 
demonstrated that the Gal-APC condensed DNA to form nanoparticles that were 
much smaller than the approximately 200 nm fenestrations of the liver sinusoid or the 
400-600 nm gap junction in the tumor vasculature, and that the galactose ligands 
present effectively and selectively enhanced gene transfection in HepG2. Although 
our in vitro results are encouraging, the true potential of this gene delivery system for 
hepatocellular carcinoma (HCC) or hepatitis viral treatments will only be evident if in 
vivo preclinical studies are performed. Although several groups have demonstrated 
increased levels of biodistribution and higher gene expression in subcutaneous HCC 
tumors due to the combined EPR effect and active ASGP-R targeting mechanism 
compared to the normal liver [182, 183], the effectiveness of our system for this 
application needs to be thoroughly evaluated. To this end, biodistribution studies can 
be first performed using fluorescently labeled Gal-APC/DNA and Glu-APC/DNA 
complexes. Luciferase gene expression in various organs can also be determined after 
tail vein injection of Gal-APC/DNA and Glu-APC/DNA complexes into nude mice 




and immunological studies should be performed to rule out any potential organ 
toxicity or non-specific interferon mediated adverse reactions arising from the 
administration of the foreign DNA complexes. Upon the successful completion of 
these studies, the next logical step would be the delivery of therapeutic genes such as 
the tumor suppressor gene, p53 using this system, followed by the subsequent 
quantification of the therapeutic outcome (e.g. reduction in tumor volume).  
In conclusion, the findings of this thesis have supported the hypothesis that 
rationally designed cationic polycarbonates with well-defined molecular architectures 
and narrow polydispersities conferred by organocatalytic ROP are highly effective 
and biocompatible non-viral gene vectors which compares favorably with the 
commercially available 25 kDa branched PEI benchmark. Through the step-wise 
modifications made to the cationic polycarbonate platform in Chapters 4 and 5, we 
have clearly established that the synthetic versatility of the system is extremely useful 
for preparing a wide range of biodegradable cationic polycarbonates with the 
exquisite tailoring of functionalities to suit the requirements of specific gene delivery 
applications. Pending successful in vivo proof-of-concept, the polycarbonate platform 
may potentially facilitate the widespread use of gene therapy in various genetic and 
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Appendix A: Synthetic procedures and characterization of functionalized 
methylcarboxytrimethylene carbonate (MTC) monomers and cationic 
polycarbonates 
 
Materials: THF, DMF, and methylene chloride used in the synthesis were obtained by 
a solvents drying system (Innovative). N-(3,5-trifluoromethyl)phenyl-N’-cyclohexyl-
thiourea (TU) and benzyl 2,2-bis(methylol)propionate (BnMPA) were prepared as 
described elsewhere [A1, A2] and dissolved in dry THF, stirred with CaH2, filtered, 
and freed of solvent in vacuo. Acetic anhydride, DMSO, N,N,N’,N’-
tetramethylethylenediamine (TMEDA), and 1,8-diazabicyclo[5,4,0]undec-7-ene 
(DBU) were stirred over CaH2, vacuum distilled, then stored over molecular sieves (3 
Ǻ). Other reagents were used as received unless especially mentioned. 
 
Characterization of Monomers and Polymers: 1H and 13C NMR spectra were 
obtained on a Bruker Avance 400 Instrument at 400 MHz. Size exclusion 
chromatography (SEC) was performed in THF at 30°C using a Waters chromatograph 
equipped with four 5 µm Waters columns (300 mm × 7.7 mm) connected in series 
with increasing pore size (10, 100, 1000, 105, 106 Ǻ), a Waters 410 differential 
refractometer for refractive index (RI) detection, and calibrated with polystyrene 
standards (750 –2 × 106 g/mol).  
 
Organocatalytic ring-opening polymerization (ROP) of functionalized MTC 
monomers: 
 
Homopolymerization of 5-Methyl-5-(3-chloropropyl)oxycarboxyl-1,3-dioxan-2-one 
(1a): 1a (250 mg, 1.1 mmol), BnMPA (4.7 mg, 0.02 mmol), and TU (9.3 mg, 0.025 
mmol) were dissolved in methylene chloride (1 mL), and this solution was transferred 
to a vial containing DBU (3.8 mg, 0.025 mmol) to start polymerization at room 
temperature ([M]0/[I]0 = 55). After 2 h, acetic anhydride (72.4 mg, 0.71 mmol) was 
added into the mixture and stirred for 2 nights (conversion ~95%). The solution was 
then precipitated into cold methanol twice and the precipitate was centrifuged and 
dried in vacuum.  Yield: 466 mg (93%), GPC (THF): Mn 12200 g/mol, PDI 1.17, 1H 
NMR (400 MHz, CDCl3):  δ 7.39-7.29 (m, 5H; ArH), 5.16 (s, 2H; PhCH2), 4.38-4.19 
(br, ~350H; CH2OCOO, OCH2 polymer), 3.64-3.55 (m, ~117H; CH2Cl polymer), 2.15-2.07 
(m, ~114H; CH2 polymer), 2.06 (s, 6H; OCH3 end group), 1.27 (br, ~169H; CH3 polymer). 
 
Homopolymerization of 5-Methyl-5-(3-bromopropyl)oxycarboxyl-1,3-dioxan-2-one 
(1b): The polymerization was conducted along the same protocol as that of 1a using 
monomer 1b (288 mg, 1.0 mmol) instead of 1a ([M]0/[I]0 = 52). Yield: 265 mg (92%), 
GPC (THF): Mn 11700 g/mol, PDI 1.11, 1H NMR (400 MHz, CDCl3):  δ 7.38-7.28 (m, 
5H; ArH), 5.17 (s, 2H; PhCH2), 4.40-4.17 (m, ~348H; CH2OCOO, OCH2 polymer), 
3.53-3.36 (m, ~111H; CH2Br polymer), 2.23-2.15 (m, ~111H; CH2 polymer), 2.06 (s, 6H; 
OCH3 end group), 1.30-1.24 (br, ~169H; CH3 polymer). 
 
Homopolymerization of 5-Methyl-5-(2-iodoethyl)oxycarboxyl-1,3-dioxan-2-one (1c): 




monomer 1c (312 mg, 1.0 mmol) instead of 1a ([M]0/[I]0 = 51). Yield: 268 mg (86%), 
GPC (THF): Mn 10500 g/mol, PDI 1.22, 1H NMR (400 MHz, CDCl3):  δ 7.37-7.31 (m, 
5H; ArH), 5.17 (s, 2H; PhCH2), 4.44-4.36 (m, ~92H; OCH2 polymer), 4.36-4.24 (m, 
~178H; CH2OCOO polymer), 3.35-3.27 (m, ~89H; CH2I polymer), 2.07 (s, 6H; OCH3 end 
group), 1.34-1.24 (br, ~144H; CH3 polymer). 
 
Random Copolymerization of 1b and 5-Methyl-5-ethyloxycarboxyl-1,3-dioxan-2-one 
(1d): 1b (282 mg, 1.0 mmol), 1d (188 mg, 1.0 mmol), BnMPA (9.0 mg, 0.04 mmol), 
and TU (18.7 mg, 0.05 mmol) were dissolved in methylene chloride (1 mL), and this 
solution was transferred to a vial containing DBU (7.8 mg, 0.05 mmol) to start 
polymerization at room, temperature ([M]0/[I]0 = 50). After 2 h, acetic anhydride (194 
mg, 1.90 mmol) was added into the mixture and stirred for 40 h (conversion 93%). 
The solution was then precipitated into cold methanol and the precipitate was 
centrifuged and dried in vacuum to obtain polymer 2d. Yield: 370 mg (77%), GPC 
(THF): Mn 11400 g/mol, PDI 1.20, 1H NMR (400 MHz, CDCl3):  δ 7.37-7.31 (m, 5H; 
ArH), 5.16 (s, 2H; PhCH2), 4.35-4.24 (m, ~247H; CH2OCOO polymer, OCH2 PC(BP)), 
4.23-4.14 (m, ~56H; OCH2 PC(Et)), 3.48-3.41 (m, ~47H; CH2Br PC(BP)), 2.23-2.14 (m, 
~47H; CH2 PC(BP)), 2.06 (s, 6H; OCH3 end group), 1.30-1.20 (m, ~227H; CH3 polymer, 
CH2CH3 PC(Et)). 
 
Quaternization of Polymers (2a-d): 
 
Quaternization of 2a: Polymer 2a (427 mg, [Cl] = 1.77 mmol) was dissolved in 
DMSO (8 mL) and mixed with TMEDA (1.1 mL, 7.22 mmol), and stirred for 6 h at 
90 °C. The mixture was then precipitated into THF twice and the precipitate was 
collected by centrifugation and dried in vacuum.  Yield: 546 mg (86 %), 1H NMR 
(400 MHz, MeOH-d4): δ 7.42-7.32 (br, 5H; ArH), 5.19 (s, 2H; PhCH2), 4.45-4.17 (m, 
~252H; CH2OCOO, OCH2 polymer), 3.63-3.44 (br, ~149H; CH2N+ polymer), 3.27-3.18 (br, 
~210H; N+CH3 polymer), 2.85-2.76 (br, ~73H; CH2N polymer), 2.36-2.30 (br, ~213H; 
NCH3 polymer), 2.28-2.17 (br, ~70H; CH2 polymer), 2.06 (s, 3H; OCH3 end group), 1.34-1.25 
(br, ~119H; CH3 polymer), 1.22 (s, 3H; CH3 end group). 
 
Quaternization of 2b: TMEDA (0.38 mL, 2.5 mmol) was added to a DMSO solution 
(3 mL) of 2b (177 mg, [Br] = 0.62 mmol). The solution was stirred overnight at room 
temperature and precipitated into THF twice, and the precipitate was centrifuged and 
dried in vacuum.  Yield: 220 mg (88%), 1H NMR (400 MHz, MeOH-d4):  δ 7.42-7.30 
(br, 5H; ArH), 5.20 (s, 2H; PhCH2), 4.46-4.13 (m, ~266H, CH2OCOO, OCH2 polymer), 
3.66-3.42 (br, ~168H; CH2N+ polymer), 3.28-3.17 (br, ~243H; N+CH3 polymer), 2.87-2.75 
(br, ~84H; NCH2 polymer), 2.37-2.29 (br, ~251H; NCH3 polymer), 2.30-2.16 (br, ~85H; 
CH2 polymer), 2.07 (s, 6H; OCH3 end group), 1.37-1.23 (br, ~133H; CH3 polymer). 
 
Quaternization of 2c: This polymer was prepared by the same procedure used for 2b 
on a 201 mg scale. Yield: 211 mg (77%), 1H NMR (400 MHz, D2O): δ 7.49-7.31 (m, 
5H; ArH), 5.22 (s, 2H; PhCH2), 4.69-4.56 (br, ~68H; OCH2 polymer), 4.47-4.23 (m, 
~176H; OCOCH2 polymer), 3.90-3.76 (br, ~74H; N+CH2 polymer), 3.66-3.51, (br, ~78H; 
OCH2CH2N+ polymer), 3.29-3.15 (br, ~220H; N+CH3 polymer), 2.93-2.82 (br, ~76H; NCH2 






Quaternization of 2d: TMEDA (0.40 mL, 2.69 mmol) was added to a DMSO solution 
(3 mL) of 2d (342 mg, [Br] = 0.67 mmol).  The solution was stirred overnight at room 
temperature and precipitated into the mixture of THF/hexane (3 : 1) twice, and the 
precipitate was centrifuged and dried in vacuum to give polymer 3d.  Yield: 494 mg 
(90%), 1H NMR (400 MHz, MeOH-d4):  δ 7.41-7.35 (br, 5H; ArH), 5.19 (s, 2H; 
PhCH2), 4.42-4.23 (m, ~253H, CH2OCOO polymer, OCH2 PC(PAB)), 4.28-4.13 (m, ~56H; 
OCH2 PC(Et)), 3.64-3.49 (br, ~96H; CH2N+ PC(PAB)), 3.28-3.19 (br, ~142H; N+CH3 
PC(PAB)), 2.84-2.75 (br, ~52H; NCH2 PC(PAB)), 2.35-2.28 (br, ~145H; NCH3 PC(PAB)), 
2.29-2.17 (br, ~49H; CH2 PC(PAB)), 2.06 (s, 6H; OCH3 end group), 1.35-1.19 (m, ~234H; 





Appendix B: Synthetic procedures and molecular characterization of PEGylated 
block copolymers and control cationic polycarbonate (without PEG) 
 
Materials: Poly(ethylene glycol)-diol (PEG-diol, Mw = 2.0 × 103 g·mol-1 and PDI = 
1.04) and monomethoxy poly(ethylene glycol) (MPEG, Mw = 2.4 × 103 g·mol-1, PDI 
= 1.05), which were purchased from Polymer Source, Canada, were freeze-dried and 
transferred to a glovebox at least one day prior to use. 2,2-
Bis(hydroxymethyl)propionic acid (bis-MPA) and N-(3,5-trifluoromethyl)phenyl-N’-
cyclohexylthiourea (TU) were prepared according to our previous protocol [A1]. TU 
was dissolved in dry THF, stirred with CaH2, filtered, and freed of solvent in vacuo. 
Prior to use, 1,8-Diazabicyclo[5,4,0]undec-7-ene (DBU) and N,N,N’,N’-
tetramethylethylenediamine (TMEDA) were stirred over CaH2 and vacuum distilled 
before being transferred to a glove box. All other chemical reagents were bought from 
Sigma-Aldrich and used as received unless especially mentioned. 
 
Synthesis of MTC-PrBr: The monomer MTC-PrBr was prepared according to the 
protocol reported in the previous work [A1]. Briefly, a solution of oxalyl chloride (3.7 
mL, 43 mmol) in 50 mL of dry THF was dropwise added into a solution of MTC-OH 
(4.6 g, 29 mmol) in 50 mL of dry THF, followed by adding a catalytic amount of 
anhydrous DMF (3 drops) over 30 min under N2 atmosphere. The reaction solution 
was stirred for 1 h, bubbled with N2 flow to remove volatiles, and evaporated under 
vacuum. The solid residue (intermediate product MTC-Cl) was then dissolved in 50 
mL of dry DCM, and a mixture of 3-bromo-1-propanol (2.4 mL, 26 mmol) and 
pyridine (2.4 mL, 30 mmol) in 50 mL of dry DCM was stepwise dropped into the 
solution over 30 min at 0°C with ice bath. The reaction mixture was kept stirring for 
0.5 h at 0°C and for another 3 h at room temperature before 300 mL of DCM was 
added. The solution was washed three times with DI water, stirred with MgSO4 
overnight and filtered. After evaporating the filtrate, the crude product was passed 
through a silica gel column by gradient eluting of ethyl acetate and hexane (50/50 to 
80/20) to provide the product as a colorless oil that slowly solidified to a white solid 
(6.8 g, 93%). 1H NMR (400 MHz, CDCl3, 22 °C): d 4.69 (d, 2H, -CH2OCOO-), 4.37 
(t, 2H, -OCH2-), 4.21 (d, 2H, -CH2OCOO-), 3.45 (t, 2H, -CH2Br), 2.23 (m, 2H, -CH2-
), 1.33 (s, 3H, -CH3). 
 
Synthesis of PEG-b-polycarbonate: The details of the procedure for ring-opening 
polymerization of MTC-PrBr with PEG-diol are given as a typical example. In a 
glovebox, PEG-diol (20 mg, 0.01mmol) and MTC-PrBr (0.42 g, 1.5 mmol) were 
added to the solution of N-(3,5-trifluoromethyl)phenyl-N’-cyclohexylthiourea (TU, 
prepared according to our previous protocol [A1], 27 mg, 0.073mmol) in 1.5 mL of 
DCM, followed by adding 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU, 11.25 mL, 
0.075 mmol) to initiate the polymerization. The reaction solution was stirred for 4 h 
before acetic anhydride (90 mL, 0.95 mmol) was added into the solution and stirred 
for 48 h. Finally, the reaction solution was purified by column chromatography on a 
Sephadex LH-20 column using THF as eluent, giving P(MTC-PrBr)-b-PEG-b-
P(MTC-PrBr) (i.e. PEG-b-[P(MTC-PrBr)]2) as colorless viscous liquid (0.39 g, 89%). 
PDI: 1.25, 1H NMR (400 MHz, CDCl3, 22 °C): d 4.28 (s, 966H, H of -CH2OCOO- 
and -OCH2-), 3.64 (s, 182H, H of PEG-diol), 3.43 (t, 322H, -CH2Br), 2.18 (m, 322H, 




PEG-b-(MTC-PrBr), Yield, 90%; PDI: 1.22. 1H NMR (400 MHz, CDCl3, 22 °C): d 
4.27 (s, 492H, H of -CH2OCOO- and -OCH2-), 3.62 (s, 218H, H of MPEG), 3.47 (t, 
164H, -CH2Br), 2.16 (m, 164H, -CH2-), 2.05 (s, 6H, H of acetyl ends), 1.26 (s, 246H, 
-CH3). 
 
Synthesis of cationic PEG-b-polycarbonate: The details of the amination procedure 
of P(MTC-PrBr)-b-PEG-b-P(MTC-PrBr) are given as a typical example. In a 
glovebox, N,N,N’,N’-tetramethylethylenediamine (TMEDA, 0.8 mL, 5.4 mmol) was 
directly added to a DMSO solution (3 mL) of P(MTC-PrBr)-b-PEG-b-P(MTC-PrBr) 
(0.39 g, [Br] = 1.3 mmol). The solution was stirred overnight at room temperature and 
precipitated into THF twice, and the precipitate was centrifuged and dried in vacuum. 
Yield, 80%, 1H NMR (400 MHz, DMSO-d6, 22 °C): d 4.04-4.33 (m, br, 212H, H of -
CH2OCOO- and -OCH2-), 3.48 (s, br, 323H, H of -CH2N+- and PEG-diol), 3.09 (s, 
212H, -N+CH3), 2.61 (s, 71H, -NCH2-), 2.15 (s, 212H, -NCH3), 2.02 (s, br, 77H, H of 
-CH2- and acetyl ends), 1.17 (s, 106H, -CH3).  
Aminated PEG-b-(MTC-PrBr), Yield, 78%; 1H NMR (400 MHz, DMSO-d6, 
22 °C): d 4.04-4.33 (m, br, 184H, H of -CH2OCOO- and -OCH2-), 3.46 (s, br, 341H, 
H of -CH2N+- and MPEG), 3.12 (s, 184H, -N+CH3), 2.64 (s, 61H, -NCH2-), 2.19 (s, 
184H, -NCH3), 2.06 (s, br, 67H, H of -CH2- and acetyl ends), 1.21 (s, 92H, -CH3). 
 
Synthesis of cationic control polycarbonate: The control polycarbonate (without 
PEG) was obtained with a similar protocol, using 2,2-bis(hydroxymethyl)propionic 
acid (bis-MPA) instead of PEG-diol (or MPEG) as initiator. Aminated bis-MPA-
P(MTC-PrBr), Yield, 70%, 1H NMR (400 MHz, DMSO-d6, 22 °C): d 7.35 (m, 5H, 
Ph-H of bis-MPA), 5.13 (s, 2H, PhCH2O- of bis-MPA), 4.08-4.37 (m, br, 249H, H of 
-CH2OCOO- and -OCH2-), 3.49 (s, 83H, H of -CH2N+-), 3.12 (s, 249H, -N+CH3), 
2.58 (s, 83H, -NCH2-), 2.20 (s, 249H, -NCH3), 2.02 (s, 89H, H of -CH2- and acetyl 




Gel permeation chromatography (GPC): GPC analysis for block copolymers was 
carried out with a Waters HPLC system equipped with a 2690D separation module 
with two Styragel HR1 and HR4E (THF) 5 mm columns (size: 300 × 7.8 mm) in 
series and a Waters 410 differential refractometer detector. The mobile phase used 
was THF with a flow rate of 1 mL/min. Number-average molecular weights as well as 
polydispersity indices were calculated from a calibration curve using a series of 
polystyrene standards with molecular weight ranging from 1,350 to 151,700. 
 
1H NMR spectroscopy: 1H NMR spectra were recorded on a Bruker Advance 400 
NMR spectrometer at 400 MHz at room temperature. The 1H NMR measurements 
were carried out with an acquisition time of 3.2 s, a pulse repetition time of 2.0 s, a 
30° pulse width, 5208-Hz spectral width, and 32 K data points. Chemical shifts were 





Appendix C: Synthetic procedures of galactose- and glucose-functionalized 
cationic polycarbonate block copolymers 
Materials: Reagents were purchased from Sigma-Aldrich and used without any other 
purification unless otherwise noted. 5-methyl-5-carboxyl-1,3-dioxan-2-one (MTC-OH) 
and N-(3,5-trifluoromethyl)phenyl-N’-cyclohexylthiourea (TU) were synthesized as 
previously reported [A1, A2]. 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) was stirred 
over CaH2, and then vacuum distilled twice before transfer to a glove box. 
Synthesis of 1,2;3,4-Di-O-isopropylidene-3-O-MCDO-D-galactopyranose (MTC-
ipGal) and 1,2;5,6-Di-O-isopropylidene-3-O-MCDO-D-glucofuranose (MTC-ipGlu): 
The monomer MTC-ipGal and MTC-ipGlu were prepared according to the protocol 
reported in the previous work [A3] and details of the procedure for preparation of 
MTC-ipGal are given below as a typical example. A solution of oxalyl chloride (2.48 
mL, 19.0 mmol) in 50 mL of dry THF was dropwise added into a solution of MTC-
OH (2.75 g, 17.2 mmol) in 50 mL of dry THF, followed by adding a catalytic amount 
of anhydrous DMF (3 drops) over 30 min under N2 atmosphere. The reaction solution 
was stirred for 1 h, bubbled with N2 flow to remove volatiles, and evaporated under 
vacuum. The solid residue (intermediate product MTC-Cl) was then dissolved in 50 
mL of dry DCM, and a mixture of 1,2;3,4-Di-O-isopropylidene-D-galactopyranose 
(ipGal, 4.13 g, 15.8 mmol) and triethylamine (2.8 mL, 20.6 mmol) in 50 mL of dry 
DCM was dropped stepwise into the solution over 30 min at room temperature. 
Subsequently, the reaction mixture was heated to 40 °C and reacted for 48 h. After 
cooling down to room temperature, the reaction solution was concentrated and 100 
mL THF was added to precipitate triethylamine salt. After evaporating the filtrate, the 
crude product was passed through a silica gel column by gradient eluting of ethyl 
acetate and hexane (20/80 to 50/50) to provide the product as a sticky colorless oil 
that slowly solidified to give a white solid (5.85 g, 85%). 
Synthesis of 3-bromopropyl 5-methyl-2-oxo-1,3-dioxane-5-carboxylate (MTC-PrBr): 
A solution of oxalyl chloride (3.7 mL, 43 mmol) in 50 mL of dry THF was added 
dropwise into a solution of MTC-OH (4.6 g, 29 mmol) in 50 mL of dry THF, 
followed by adding a catalytic amount of anhydrous DMF (3 drops) over 30 min 
under N2 atmosphere. The reaction solution was stirred for 1 h, bubbled with N2 flow 
to remove volatiles, and evaporated under vacuum. The solid residue (intermediate 
product MTC-Cl) was then dissolved in 50 mL of dry DCM, and a mixture of 3-
bromo-1-propanol (2.4 mL, 26 mmol) and pyridine (2.4 mL, 30 mmol) in 50 mL of 
dry DCM was stepwise dropped into the solution over 30 min at 0°C with ice bath. 
The reaction mixture was kept stirring for 0.5 h at 0°C and for another 3 h at room 
temperature before 300 mL of DCM was added. The solution was washed three times 
with DI water, stirred with MgSO4 overnight and filtered. After evaporating the 
filtrate, the crude product was passed through a silica gel column by gradient eluting 
of ethyl acetate and hexane (50/50 to 80/20) to provide the product as a colorless oil 
that slowly solidified to a white solid (6.8 g, 93%). 
Synthesis of functional polycarbonates: The detailed procedure for synthesis of 
functional polycarbonate using MTC-ipGal and MTC-PrBr is given below as a typical 
example. In a glove box, MTC-ipGal (0.193 g, 0.48 mmol) was added to the solution 
of 4-methylbenzyl alcohol (MBA, 2.99 mg, 0.024 mmol) in 2 mL of DCM, followed 




9.0 mL, 0.06 mmol) to initiate the polymerization. The reaction solution was stirred 
for 1.5 h, and then MTC-PrBr (0.338 g, 1.2 mmol) was added and reacted for another 
4 h before acetic anhydride (81 mL, 0.95 mmol) was added into the solution and 
stirred for 48 h. Finally, the reaction solution was precipitated in cold MeOH twice, 
washed and dried in vacuo (0.43 g, 80%). 
The above polymer was dissolved in an aqueous solution (4 mL of formic acid and 
1 mL of deionized water) and stirred for 48 h before being dialyzed against 
acetonitrile for 24 h and against water for another 24 h using 1000 kDa membrane 
cutoff and with solvent change occurring every 6 h. The solution in the dialysis bag 
was then transferred in a vial and freeze-dried to give a white powder in good yields 
(0.39 g, 86%).                                                                                      
The resulted powder was dissolved in 3 mL of DMSO, following by adding 
N,N,N’,N’-tetramethylethane-1,2-diamine (TMEDA, 572 mL, 3.84 mmol) and stirred 
overnight. Finally, the reaction solution was precipitated in THF twice, washed and 
dried in vacuo (0.42 g, 83%). 
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